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INTRODUCTION
"A" The Fibrinolytic System
The fact that shed blood clots has been known to man since time
immemorial and he has been aware of its protective action in the
presence of those noxious stimuli which cause bleeding. Thousands
of years ago, the physicians of Ancient Egypt preached the value of
the application of raw meat to fresh wounds (Ghalioungui, 1961). More
recently tissue extracts have been found to contain an essential factor
in the extrinsic system of blood coagulation, so that when added to
plasma they cause the latter to clot, a property on which the well
known test, the Quick one stage prothrombin time is based (Quick, 1935).
It has only been appreciated more recently, however, that ultimately
a solid blood clot normailLy undergoes 'dissolution' and 'liquefaction'.
The observation that5after sudden death of a person the blood clots
and liquefies spontaneously afterwards^was first made more than 200 years
ago by the Italian anatomist and pathologist Giovanni Bathista Morgagni
(1761) and some years later, the famous English surgeon and anatomist
John Hunter (1794-) reaffirmed this fact. Other important historical
findings on the subject followed such as, the time for lysis of the clot
(Denis, 1838)? non-coagulability of fibrin once it had liquefied (Green,
1887), and the role of chloroform, ether and thymol in the activation of
'fibrinolysis' (Denys and Marbaix, 1889). In 1893, the process of lysis
of a blood clot was firmly established as an entity by the French biochemist
Dastre who coined the term 'fibrinolysis' for it and by 1903, Hedin had
demonstrated that the factor responsible for fibrinolysis resided in the
globulin fraction of serum.
The experimental production of an in vivo fibrinolysis by peptone
injections in dogs was achieved in 1905 by Nolf. It was not, however,
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until 1933 after Tillet and Garner showed that extracts of beta
haemolytic streptococci caused the lysis of plasma clots that the
new field for the application of fibrinolysis in the treatment of
thromboembolic conditions could be considered.
A few years later, Yudin in Russia (1936) started to use cadaver
blood for transfusions, selecting persons who died from sudden accidents
since these were (a) previously healthy and (b) because their blood
underwent rapid liquefaction and thus could be used without anticoagulants.
One of the major contributions to oar modern knowledge on fibrinolysis
stems from the work of Macfarlane begun some 25 years ago by the invest¬
igation of fibrinolysis in patients who had undergone surgical operations
(Macfarlane, 1937). This work, in which for the first time methods were
presented for measuring the degree of fibrinolysis, opened the way to the
study of the implications of fibrinolysis in various clinical states.
Despite the great amount of investigation which followed, so that now the
literature on the subject is voluminous, our knowledge on the basic stages
of the process is still not unequivocally established and much work remains
to be done. In fact, even one of the main potential applications of
fibrinolysis in clinical medicine which is the use of some of its components
or activators for inducing therapeutic thrombolysis still remains in the
experimental stage.
Added to the lack of knowledge about fibrinolysis is the confusion
that exists about the subject. This has been caused by the fact that
different investigators have given many names to alleged components of
the fibrinolytic system with the result that different appellations have
often been given to the same constituent and sometimes the constituents
on further investigation have proved to be artefacts. This confusion
stresses the need for an agreement on the identity and names of the components
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of the system so that an International Nomenclature can be established.
(1) Study of the Fibrinolytic System in Hereditary and
Congenital Coagulation Defects.
The association of classical haemophilia (haemophilia due to
reduction of factor ¥111) with other coagulation disorders has been
described not infrequently in the literature. Factor VIII deficiency
has been reported in combination with deficiency of factor V (Seibert,
Margolius and Ratnoff, 1958), of factor VII (Gaston, Mach and Beck,
1961), of factor IX (Sj/lin, 1957) and of factor XI (plasma thromboplastin
antecedent, P.T.A.) (Scardigli and Guidi, 1956). Deficiency of factor
VIII has also been reported in association with a congenital vascular
defect and platelet abnormality (Raccuglia and Neel, i960) and with an
ill defined freezing/serum factor (Sj/lin, 1959)• The presence of
reduced factor VIII levels in some cases of von Willebrand's disease
(Nilsson and Blomback, 1959), is now well known to all workers in the
field of coagulation disorders. There have only been a few reports of
cases where the fibrinolytic system has been studied in relation to
haemophilia and in these, the results have been inconsistent (Tagnon,
Davidson and Taylor, 194-3; Lewis, Davidson, Soulier, Tagnon and Taylor,
194.6; Guest, Daly, Ware and Seegers, 194-8; Richert, 194-9).
Because there have been few reports of the fibrinolytic system
in hereditary and familial haemorrhagic disorders, our knowledge on the
matter is scanty. Experimentally, however, it has been customary to regard
the level of factor VIII and the degree of fibrinolytic activity as being
related in an inverse manner that is, the level of factor VIII diminishes
when there is an increase in fibrinolytic activity. This is demonstrated
in thei&'peutic trials of fibrinolytic agents, where factors I (fibrinogen),
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V and VIII have been shown to decrease after the administration of
large doses of fibrinolysins. These three factors have very similar
physico-chemical properties and behave oppositely to the 'prothrombin
group' of factors, namely II (prothrombin), VII, IX and X all of
which remain unaffected (Roller, 1961). Stefanini and Gendel (1953)
report, however, that increased fibrinolysis may cause excessive
destruction of all known coagulation factors. In spontaneous crises
and post-operatively in haemophilia where the level of factor VIII
(A.H.G.) may decrease, it is not known whether this decrease is a
primary one, or else secondarily aggravated by the presence of a
potent fibrinolysin (Davies, 1961).
The investigation of the fibrinolytic system in haemophilia and in
congenital and hereditary haemorrhagic disorders appeared to be especially
useful as a means of evaluating the theory that haemostasis is a
continuous process in a state of dynamic equilibrium. The theory implies
continuous deposition of fibrin on the vascular endothelial lining and
its balanced removal under two opposing forces of coagulation and
fibrinolysis. It v&s thought that if the theory held true, a disturbance
of one of the processes, as in haemophilia and some other bleeding
disorders, would be followed by a similar disturbance in the opposing
process, that is in fibr5.nolysis. The subject will be discussed in more
detail later.
(2) Study of the Changes in the Fibrinolytic System During Extracorporeal
Circulation for Open-Heart Surgery.
During extracorporeal circulation for open-heart surgery, bleeding
tendencies have been reported and there has been a wide diversity of
opinion about their aetiology (see p. 61). An excessive activation of
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the fibrinolytic system has been more frequently reported than any other
cause, and in some cases has lead to serious bleeding episodes. The
cause of the sudden activation of the fibrinolytic mechanism has been
the subject of much speculation. Many factors have been blamed
including the type of apparatus used, the duration of perfusion,
active trauma, massive transfusion, blood incompatibility, inadequate
cleaning of equipment, the type of cardiac lesion and especially
thromboplastin activation. Agreement, however, on the changes
occurring in factors involved in the fibrinolytic and coagulation systems
during extracorporeal bypass is far from unanimous.
Because of these controversies concerning the fibrinolytic
system in hereditary and congenital haemorrhagic disorders and
during extracorporeal circulation, it was decided to investigate
the changes occurring in this system with the aims of a.) improving
the assay methods for various components of the system, b) studying
the various components of the fibrinolytic system in congenital
and hereditary haemorrhagic diseases, to determine the behaviour
of these with operative procedures and above all to evaluate the
theory of continuous fibrin formation and 'dissolution', c. )
determining the changes occurring during cardiopulmonary bypass
using the Melrose N.E.P. oxygenator and heart-lung machine with
hypothermia.
"B". Haptoglobin Types in Scotland and in Scottish Haemophilics.
Polonovski and Jayle in 1939 found that the peroxidase activity
of haemoglobin of different species xjas greatly increased when plasma
was added to it, and this phenomenon was shown to vary with pathological
states. The same authors demonstrated that the responsible agent for
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this activity resided in the proteins of the plasma. These have been
recently isolated and ©ailed haptoglobins (Hp) because of their
interaction with haemoglobin (Hb) (Laurell and Nyman, 1957) and their
chemical and physical properties have been studied (Jayle and Boussier,
1954.j Guinand, Tonnelat, Boussier and Jayle, 1956).
In 1955 Smithies demonstrated that there are three types of
haptoglobins. These are now known to be genetically determined by
a pair of autosomal allelic genes. Haptoglobin levels have been found to
vary with disease entities though no definite relationship has been found
between haptoglobin types, transferrin types and various diseases.
Reports on such associations have been contradictory (Bennett, 1961).
Harris, Robson and Siniscalco (1959) consider that this work should be
extended.
It was decided to study the haptoglobin phenotypes in haemophilics
in comparison with normal, people domiciled in the same area in an endeavour
to detect possibly a genetic linkage and to throw more light on the
equivocal relation between haptoglobin types and/or blood groups, and
various disease conditions in general.
"C". Circulating Anticoagulants in Factor VIII Deficiency
There are, in Scotland, approximately 220 known sufferers from *.
factor Till and factor IX deficiency. Of these, it is estimated that
about 110 are severely affected patients i.e. who suffer repetitive
spontaneous bleeding throughout their lives. Severely affected
haemophilics tend to average at least one admission per year to hospital
in their childhood and early adult life, ranging from minor episodes of
2-3 week$! duration to more major ones that may last several months
(Davies, I96I).
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During hospitalization, haemophilias frequently require fresh blood
or plasma transfusions or antihaemophilic fraction (A.H.F.) but despite the
large volume of such products used in the treatment of these patients,
the reported acquired circulating anticoagulants have not been frequent.
Among 67 registered haemophilics living in South East Scotland, only one
case during the last A years was known to develop a circulating anti¬
coagulant which destroyed factor VIII. The patient was a severe haemophilic
undergoing dental extraction. The anticoagulant occurred late in his
post-operative treatment and whilst proving troublesome was not lethal.
An unusual case of another haemophilic in whom a circulating
anticoagulant had developed and who was admitted to the Royal Infirmary
of Edinburgh from Northern England was studied. In this patient the
circulating anticoagulant was unusual in that it did not destroy factor
VIII but prevented thromboplastin generation, proved refractory to
treatment and the patient died. A clinical and laboratory study of the























































































The mechanism of blood clotting is a ramified process designed
for the precipitation of fibrin, the fibrils of which interlace to
enmesh not only the liquid plasma but also the formed elements
of blood (Hoffman, 1955). This phenomenon involves the interplay
of complex protein substances, most of which have not been isolated
in pure form.
Our knowledge of blood coagulation can be divided into three
eras by the classical theory of Morawitz postulated in 1904-. These
three eras are the pre-classical the classical and the post-classical.
In the classical theory, prothrombin is converted to thrombin by
the action of thromboplastin and calcium and the thrombin then converts
fibrinogen to fibrin. Within certain limits, the Morawitz theory
is still valid.
The post-classical era began in 194-3 following renewed interest
in, and investigations of, Quick's one stage prothrombin test and has
culminated in the general recognition of the existence of twelve
separate factors essential for the formation of a normal clot (Douglas,
I962). These factors have now been numbered internationally
(international Nomenclature Committee, J. Amer. med. Ass., 170, 325,
May, 1959) which has considerably clarified the problem in that
many workers had separately described and named factors which have
subsequently proved to be the same factor. These factors with




International Nomenclature of Coagulation Factors




III Thromboplastin (tissue extract), thrombokinase.
IV Calcium
V Labile factor, plasma accelerator globulin,
proaccelerin, plasma prothrombin conversion factor.
VI Not used at the present time.
VII Stable factor, serum prothrombin conversion
accelerator (SJP.CA-), proconvertin.
VIII Antihaemophilic globulin (A.H.G.), antihaemophilic
factor (A.H.F.), antihaemophilic globulin A,
thromboplastinogen, platelet co-factor I.
IX Christmas factor, plasma thromboplastin component
(P.T.G.), antihaemophilic globulin B, platelet co-factor II.
X Stuart-Prower factor.
XI Plasma thromboplastin antecedent (P.T.A.),
Rosenthal factor.
XII Hageman factor, contact factor.
There is no general agreement on the role of each factor in the
coagulation process which results in the formation of a solid blood clot.
Figure 1 shows a scheme of the interaction of the various factors
participating in the clotting mechanism in which there are three stages
and which normally leads to the formation of and the deposition of fibrin.
Other elements which may participate in the clotting mechanism but for
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which experimental proof or function is uncertain such as the erythrocyte
factor, electric charge, mineral salts apart from calcium, water
wettability, pH of medium, enzymes, amino acids and oxidizing agents
have been omitted.
Figure 1
Clot Formation and Digestion in vitro
First Stage : Formation of prothrombin activator.
b. Intrinsic System
Activated Factor XII (contact factor or
Hageman factor-activated)
Activated factor XI (P.T.A.)
Activated factor IX (Christmas factor)




Factor X (Stuart-Prower factor)
Second Stage : Thrombin generation
Prothrombin activator
Factor II (prothrombin) Thrombin
(Extrinsic or intrinsic)
Third Stage : Fibrin formation.
Thrombin
Factor I (fibrinogen) > Fibrin monomer + fibrinopeptides
Fibrin monomer > Fibrin polymer
Fibrin polymer Fibrin stabilizing factory Fibrin
Factor IV"(Calcium)
A fourth stage, of no less importance than the preceding three, that
of fibrin digestion or fibrinolysis, serves to remove the normal fibrin
structure when it is no longer required. A proposed scheme for the
a. Extrinsic System
Factor V






interaction of the various components of this stage of fibrinolysis is shorn
in figure two.
It has been claimed that coagulation and fibrinolysis that is the
deposition of fibrin on, and the removal of fibrin from the vascular
endothelium is in a state of dynamic equilibrium. It has been said that
this equilibrium ensures the integrity of blood vessels without impairing
the vitality of organs supplied by them. The assumption of such an
equilibrium is an attractive hypothesis which it is one purpose of this
study to evaluate on the basis of investigations into the fibrinolytic
system in some cases of congenital and hereditary haemorrhagic disorders
(see p 51 ).
Role of the Fibrinolytic System
Whilst emphasis is usually placed on the action of the fibrinolytic
system within the vascular tree, it should be remembered that fibrin
deposition can also occur extravascularly as in the presence of inflammation
and that the fibrinolytic mechanism is therefore best considered as a
generalized reparative process. The system is concerned with limiting
inflammatory spread, with the healing of wounds and with maintaining the
patency of duct systems in general (blood vessels, ureters, lacrymal and
milk ducts etc.). It is probably involved in anaphylactic reactions
(Ungar, 194-7), in body protein catabolism and possibly in some manifestations
of the inflammatory process such as pain, increased permeability and
oedema (Biggs and Macfarlane, I962). It is not clear whether fibrinolysis
takes an active part in the clotting process itself. Recent interest in
the fibrinolytic system has been stimulated by the potential use of
fibrinolytic agents in the treatment of thrombotic and embolic states.
Nomenclature
All mammalian blood contains a significant amount of an enzyme
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precursor which on activation, can rapidly hydrolyse fibrin and some other
proteinSo This precursor 'plasminogen* or 'profibrinolysin' in its active
form is known as 'plasmin' or •fibrinolysin' respectively, and the first
terms are best used in that the active enzyme digests not only fibrin but
various other proteins as well (Christensen and MacLeod, 194-5)♦ Where it
is intended to restrict the action to fibrin, the terms 'fibrinolysis' and
'fibrinolytic activity' should be used. The terms 'thrombolysis' and
'thrombolytic activity' are used to describe the entire mechanism whereby
thrombi or fibrinous exudates are lysed; and 'proteolysis' and 'proteolytic
activity' are used to describe the overall action on proteins in general.
When the blood plasmin level is high, the term 'hyperplasminaemia' can be
used. It is strongly suggested that the term 'inhibitors' used by some
workers as a synonym for 'circulating anticoagulants' (Nour-Eldin and
Wilkinson, 1958; Israels, Foerster and Zipursky, i960), should be restricted
to inhibitors of the fibrinolytic system which comprise both 'inactivators'
and 'antiplasmins' (figure 2). Many reviews of fibrinolysis (Christensen,
195A; Astrup, 1956; Mullertz, 1956; Sherry and Alkjaersig, 1957;
Sherry, Fletcher and Alkjaersig, 1959) have been published.
Variations in the Blood 'Fibrinolytic Activity'
in Response to Physiological. Experimental and Pathological
Conditions
Sterile clots of blood and plasma undergo various degrees of lysis
after extended periods of incubation due to the spontaneous occurrence of
low levels of fibrinolytic activity in normal individuals (Fearnley and Tweed,
1953; Fearnley and Lackner, 1955)• The phenomenon may be accelerated by
mere dilution of the plasma (Macfarlane, 1937; Macfarlane and Pilling, I9A6;
Bidwell, 1953; Fearnley and Tweed, 1953). A diurnal fluctuation in
fibrinolytic activity has been observed by Buckell and Elliott (1959 a) and
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has been confirmed in this study (see p. 4-8). There are suggestions that
the fibrinolytic system of the newborn infant may differ from that in
the adult (Quie and Wannamaker, i960).
Besides therapeutically induced fibrinolysis which will be discussed
later, various stimuli have been shown to enhance the fibrinolytic
activity of blood, such as mental stress (Macfarlane and Biggs, 194-6),
physical exercise (Bidwell, 1953) and menstruation on the first day (Smith
and Smith, 194-5). The rise in fibrinolytic activity after prolonged
heavy exercise is soon followed by a fall (Ogston, 1961), The injection of
adrenaline causes a rise in the fibrinolytic activity (Biggs, Macfarlane and
Pilling, 194-7) although this effect has been questioned (Truelove, 1951).
Increased fibrinolytic activity has also been described after anoxia (Tagnon,
Levenson, Davidson and Taylor, 194-6) and local ischaemia (Kwaan, Lo and
McFadzean (1957; 1958). Sforza and Pozzi (i960) found in normal males
and females breathing various gas mixtures an increase in plasma fibrinolysis
which was proportional to any increase in CO^ tension or reduction in 0^
tension. Excessive fibrinolytic activity following sudden anoxaemic
death (Mullertz, 1952 a) had long been made use of by the Russians to obtain
large volumes of blood from fresh cadavers for transfusion purposes
(Yudin, 1936; Tarasov, i960) and in countries where volountary blood
donations are scarce and professional bleeders are relatively expensive this
might be an attractive proposition.
Increased fibrinolytic activity in vivo has been found following large
doses of intravenous acetylcholine by Soulier and Koupernik (194-8), after
intravenous pyrogens by von Kaulla (1958), after nicotinic acid by Weiner,
Redisch and Steele (1958) and following the administration of a fungal
agent, Aspergillin 0 by Karaca, Stefanini and Mele (1962). Fantl and Simon
(1958) reported increased fibrinolytic activity in patients after electric
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shock therapy and Cliffton (1952) observed the same phenomenon with
anaphylactic shock, X-ray therapy, and paradoxically after A.C.T.H.
and cortisone administration since A.C.T.H., together with fresh blood
transfusion and fibrinogen, has been recommended for the treatment of
fibrinolytic states by Stefanini and Dameshek (1955) and by Biggs and
Macfarlane (1962).
Tissue damage is, however, the best known cause of activation of
the fibrinolytic system. This is illustrated by the enhanced fibrinolytic
activity in burns, during various operative manipulations and in shock
(Tagnon, Levenson, Davidson and Taylor, 194-6; Sforza and Pozzi, I960 a)
and especially following operations on the lungs, (Baumann, 1951), the
prostate (Rollason and Shillitoe, 1954-), in cranial injuries (Sforza and
Pozzi, i960 b) and in some obstetrical and gynaecological conditions
(Reid, Weiner, Roby and Diamond, 1953; Ratnoff, Pritchard and Colopy,
1955). An increased activity has also been found in various disease
states in particular in, liver and spleen diseases (Kwaan and McFadzean,
1956; Kwaan, McFadzean and Cook, 1957; de Nicola and Soardi, 1958), in
certain haematological disorders such as polycythaemia vera (Bj6rkman,
Laurell and Nilsson, 1956), leukaemia (Cooperberg and Neiman, 1955) and
multiple myelomatosis (Sirridge, Bowman and Garber, 1958) and in the course
of some neoplastic diseases (Brown, Campbell and Thompson, I962).
A decrease in fibrinolytic activity has been reported to occur
physiologically in late pregnancy (Biezenski and Moore, 1958) and with
alimentary lipaemia (Buckell and Elliott, 1959). Pathologically
fibrinolytic activity is decreased in congestive heart failure and
atherosclerosis (Sawyer, Fletcher, Alkjaersig and Sherry, i960) and in
hyaline membrane disease (Lieberman, 1961).
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Mullertz (1956; 1957) showed that small amounts of plasminogen
activator exist in the normal circulation and the normal fibrinolytic
activity of the blood may be due to it and not to the free active
enzyme, plasmin. This principle may also be true in the increased
response to physiological and pathological stimuli (Sherry, Lindemeyer,
Fletcher and Alkjaersig, 1959). This increased activity is thrombolytic
or fibrinolytic and not fibrinogenolytic (Bidwell, 1953; Fantl and
Simon, 1958) or esterolytic (Schultz, Moorman, Matoush and Lincoln,
1957) and the process is independent of the proteolytic activity
of the plasma (Ratnoff, 194-8). All these features are characteristic
of an activator action and not of free plasmin. Sawyer, Fletcher,
Alkjaersig and Sherry (i960) showed that the degree of thrombolytic
activity is determined by the level of plasminogen activator. This is
supported by the fact that the increased activity during physiological
stimuli can be sharply depressed by the action of epsilon amino caproic
acid (E.A.C.A.) - an inhibitor of the plasminogen activator - when given
in doses insufficient to reduce plasmin activity and also by the fact
that there is no definite proof that reduction in antiplasmin levels has
ever resulted in an enhanced fibrinolytic activity (Sherry, Fletcher and
Alkjaersig (1959). Kwaan, Lo and MacFadzean (1957; 1958; 1958 a),
studying fibrinolytic activity in vivo have produced evidence of the
existence of a cholinergic effector mechanism in vessel walls which
responds to ischaemia (locally and reflexly) by the release of activator
into the circulation. Sherry, Lindemeyer, Fletcher and Alkjaersig (1959)
studied the proteolytic activity of blood after electric shock, pyrogen
injection and sever exercise and. found an increase in its activity to be
due to the presence of a plasminogen activator but they failed to find
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any significant changes in plasmin, plasminogen, antiplasmin or
fibrinogen.
There would-a.ppear to be at least two possible mechanisms
causing uncontrollable fibrinolysis (hyperplasminaemia), the first
causing the release of excessive quantities of activator from the
tissues and the second to be due to the release of thromboplastic
material which thereby results in a secondary fibrinolytic state.
The clinical aspect is often too comples for present techniques to
solve.
Bleeding Due to Excessive Fibrinolysis
The fibrinolytic haemorrhagie states seen during and immediately
following operation and rarely non-surgical are sudden and unpredictable
in onset. The bleeding endangers life, fibrinogen being completely
absent in the circulating blood. The condition is transitory and is
treated by transfusion of fresh blood and the administration of A.C.T.H
and fibrinogen (Stefanini and Dameshek, 1955)•
Plasminogen
Plasminogen (profibrinolysin) is the inactive percursor of the
active enzyme plasmin or fibrinolysin. Plasminogen present in the
plasma has the characteristics of a gamma globulin (Lewis, Walters,
Didisheim and Merchant, 1958). The suggestion of Barnhart and Riddle
(1961) that eosinophils might synthesize and transport plasminogen is
yet to be confirmed. Plasminogen may be precipitated from plasma
or serum at pH 5.3 and low' ionic strength (Sherry, Fletcher and Alkjaersig,
l959)o Remmert and Cohen (194-9), Kline (1953) and Fletcher (1954-)
have described methods for the purification of plasminogen from plasma;
and recently plasminogen has been isolated from Cohn fraction III with
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an increase in specific activity of about 4-00 times compared to that
of serum (Kline and Fishman, I96I a).
The physico-chemical properties of plasminogen have been studied
by Shulman, Alkjaersig and Sherry (1958) and the physical properties
by Davies and Englert (i960). A calculated molecular weight of
83,800 for highly purified human plasminogen has been reported by
the latter investigators. Purified plasminogen is sparingly soluble
at neutral pH, but is soluble below pH 4..0 and above pH 8.6. There
are indications that plasminogen may be a glycoprotein since plasminogen
preparations contain about 1% trichloracetic acid - insoluble hexose,.
part of which is rendered trichloracetic acid - soluble during its
activation (Alkjaersig, Fletcher and Sherry, 1958; 1958 a; Shulman,
Alkjaersig and Sherry, 1958). Phosphorus seems to be a constituent
element of the plasminogen molecule because it remains even after
prolonged dialysis (Shulman, Alkjaersig and Sherry, 1958).
Plasminogen has a tremendous affinity for fibrinogen and for fibrin.
Fibrinogen and fibrin preparations free from adsorbed plasminogen are
difficult to obtain unless special methods are used to denature
plasminogen (Lassen, 1952) as for example the heating process in the
preparation of fibrin plates. On the other hand, separation of
plasminogen from fibrinogen does not present a problem. In various
exudates and transudates, a correlation exists between plasminogen and
fibrinogen levels; where fibrinogen is low or absent plasminogen is
reduced or absent and vice versa (Christensen, 1954-). The biochemical
basis for the affinity between plasminogen and fibrinogen or fibrin has
not been determined.
Differences have been reported between the plasminogen of different
species, and starch-gel electrophoresis in acid medium of bovine and human
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plasminogen gave different patterns (Gole and Mertz, 1961 a)e
Stability of plasminogen; (Christensen and Smith, 1950; Troll
and Sherry, 1955; Ablondi and Hagan, 1957; Lassen, 1958).
Plasma plasminogen appears to be stable at moderate temperatures
over a wide pH range. Purified plasminogen preparations are, however,
relatively unstable at neutral and alkaline pH. Below pH 4-.0,
purified plasminogen is quite stable and may be brought to 100°C. at
pH 2.0 without significant loss of activity (Sherry, 1954-; Troll and
Sherry, 1955).
Proactivator
The nature of a hypothetical serum and plasma proactivator has been
the subject of considerable controversy. The hypothetical basis for
the presence of such an activator is based on observations of the
varying behaviour of streptokinase towards activation of plasminogen
in different species. Streptokinase (SK) is a bacterial protein
which transforms inactive plasminogen into active plasmin. SK which
readily activates human plasminogen has almost no action on bovine and
porcine plasminogen (Cliffton and Downie, 1950), unless small quantities
of human serum are added (Mullertz and Lassen, 1953; Sherry, 1954-;
Troll and Sherry, 1955). It has been deduced, therefore, that human
serum contains a substance termed proactivator (Mullertz and Lassen,
1953; Astrup, 1956 a; Mullertz, 1956) which is absent in bovine and
porcine sera. Further, the activation of human plasminogen by SK
takes place in a two-step manner. SK first reacts stoichiometrically
and perhaps reversibly with a serum factor to produce an activator. This
activator then enzymatically activates plasminogen by first order kinetics
(Mullertz and Lassen, 1953; Mullertz, 1955; Troll and Sherry, 1955;
Sherry and Alkjaersig, 1957; Alkjaersig, Fletcher and Sherry, 1958 a).
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Differential stability studies lend support to the existence of
such a proactivator (Troll and Sherry, 1955; Mullertz 1957; Lassen,
1958).
The main confusion regarding the nature of proactivator is whether
it is linked in some way to human plasminogen or is a distinct entity
(Troll and Sherry, 1955; Ablondi and Hagan, 1957; KLine and Fishman,
1957; Mullertz, 1957; Sherry and Alkjaersig, 1957; Baumgarten, Cole,
Richard and Smith, 1958). Evidence associating proactivator activity
with human plasminogen has been produced (Sherry, 1954; Ablondi and
Hagan, 1957; Kline and Fishman, 1957; Sherry and Alkjaersig, 1957;
Hagan, Ablondi and De Renzo, i960) and in all purification techniques
so far employed, the proactivator activity parallels exactly that of
the human plasminogen content of the purified fractions. Lassen (1958)
has argued, however, that plasminogen cannot be identical with
proactivator since during the conversion of the latter to activator,
the plasminogen and plasmin concentrations remain unchanged.
Kline and Fishman (1961) have demonstrated a proactivator function
of human plasmin by a lysine esterase assay.
Activators
Our knowledge about the activation of the plasminogen system is very
incomplete since most of the factors concerned have not been identified
nor has their mode of action been determined. The following classification
of in vitro activators which is a modified version of Sherry, Fletcher
and Alkjaersig (1959) is recommended.
A. Naturally occurring activators
1. Tissue activators.










1. Chloroform and other organic solvents.
2. Peptone.
3. Urea and aromatic derivatives; hydrotropic substances.
A. Waturally Occurring Activators :
1. Tissue activators. Tissue kinases or fibrinokinases.
Various animal tissues have been shown to possess an activating
action on the plasminogen system (Astrup and Permin, 194-7; Permin, 194-7;
Astrup, 1951). These tissue activators can be extracted in soluble form
by concentrated potassium thiocyanate solutions (Astrup and Sterndorff,
1956; 1956 a). Different tissues vary considerably in their activator
content (Albrechtsen, 1957; 1957 a; Roberts and Astrup, 1957; Astrup
and Sj/lin, 1958);in man, lung and brain have the highest concentration
(Cohn and Warren, 1961) and the prostate, the thyroid and the uterus
also have specially high concentrations (McNicol, 1962).
Todd (1955) described a histological technique for the detection of
fibrinolytic activity in tissues. His results sho\7 that fibrinolytic
activators in human tissues are concentrated principally in the
endothelium of veins, venules and the pulmonary arteries. It has been
claimed that the adventitia in the aorta has a high concentration of
activators, whereas the intima and media contain thromboplastin (Cohen
and Warren, 1961).
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The presence of large amounts of activators of the plasminogen
system in many tissues and the close affinity of plasminogen for
fibrin, lends support to the concept that fibrinolysis via the
plasminogen system is of major importance in the resolution of
inflammatory and traumatic fibrinous exudate.
Tissue activators are fairly thermostable particularly at acid
pH, but gross impurities in the preparations have prevented further
identification and it remains to be established whether the activators
produced by different tissues are similar (Sherry, Fletcher and
Alkjaersig, 1959).
2. Activators in plasma and other biological fluids. Trace amounts
of activators may be present in the circulation of normal individuals
(Mullertz, 1956; 1957). Activators have also been detected in bodily
secretions such as human milk (Astrup and Sterndorff, 1953), tears
(Storm, 1955), saliva (Albrechtsen and Tbaysen, 1955) and seminal fluid
(von Kaulla and Shettles, 1953). Activators have also been demonstrated
in patients after acute anoxaemic episodes (Mullertz, 1953), amniotic
fluid embolism (Albrechtsen, Storm and Trolle, 1955), electric shock,
pyrogen administration, exercise, ischaemia and epinephrine (Mullertz,
1953). Increased fibrinolytic activity in response to various
physiological and pathological stimuli is due to the release of
activators (see p. 16).
The activity of activators is almost wholly precipitated with the
plasma euglobulin fraction (Mullertz, 1956; 1957). Like most of the
coagulation factors and fibrinolysins, however, they have never been
isolated in pure state for further characterization. Activator activity
in the plasma is much less stable than are activators in tissues; its
instability may be related to various inhibitors in the blood (Douglas,
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1962). During the clotting process plasma activators are partially
adsorbed on to the fibrin coagulum and it is by this local means,
and not in the general circulation that they act on the fibrin,,
3. Urinary activators. The urinary activator of plasminogen has
been called urokinase by Sobel, Mohler, Jones, Dowdy and Guest (1952).
In normal individuals urokinase concentrations are similar in male and
female urine Bj errehuus, 1952), independent of age and urine volume,
but alter in diseases (Sherry, Fletcher and Alkjaersig, 1959).
Astrup and Sterndorff (1952), suggest that urokinase may not be
a simple excretion product but that it is locally produced in the
kidneys in order to maintain the patency of the urinary system. Recent
investigations suggest that urokinase excretion may represent, at least
in part, excreted plasminogen activator (McNicol, Fletcher and Sherry,
i960); von Kaulla and Swan (1958) report an increased excretion of
urokinase in patients who developed fibrinolytic states during cardiac
surgery, returning to normal levels as the intensity of the fibrinolytic
state declined.
Urokinase itself seems to be capable of protein digestion. In
high concentrations it acts in varying degrees on casein, the basic
amino acid esters tosyl arginine methyl ester and lysine ethyl ester,
and on a heparin-protamine complex (Kjeldgaard and Ploug, 1957;
Sherry and Alkjaersig, 1957; Alkjaersig, Fletcher and Sherry, 1958 a).
Urokinase forms 37% of the total urinary proteins as shown by
electrophoretic studies (Sherry, Fletcher and Alkjaersig, 1959). Urokinase
is non dialyzable, active at neutral pH, and although more stable than
the activator in milk, tears and saliva, it is labile in acid solutions
(Cohen and Warren, I96I). It is heat stable up to 50°C.and Stable over
24
a wide pH range (Ploug and Kjeldgaard, 1957).
4. Trypsin. Trypsin is a plasminogen activator (Kocholaty, Ellis
and Jensen, 1952; Alkjaersig, Fletcher and Sherry, 1953 a) but acts
relatively slowly as compared to the specific activators (SK and
urokinase) and differs from them in that it produces a higher percent¬
age of trichloracetic acid-soluble fragments and its action is not
competitively inhibited by epsilon amino caproic acid in contradistinction
to the action of the specific activators (Sherry, Fletcher and Alkjaersig,
1959).
5. Plasmin. Purified preparations of plasminogen undergo spontaneous
activation at neutral pH but the yield of plasmin under these circumstances
is poor due to the instability of both plasmin and its precursor under
these conditions. This, activation may be autocatalytic for it is known
that plasmin when added to activator accelerates its action whereas
plasmin substrates inhibit it. The activation of plasminogen by plasmin
closely resembles that observed with trypsin.
6. Phosphatases. Claims that phosphatases are the main activators of
plasminogen with subsequent major effects on the fibrinolytic system
(Misirlioglu and Lillehei, 1962) remain to be decided.
B. Activators of Bacterial Origin.
1. Streptokinase (SK). In 1933 Tillett and Garner in hew York discovered
that rapid lysis occurred in plasma clots incubated with extracts of
beta haemolytic streptococci. This is now known to be due to the
bacterial enzyme streptokinase. Streptokinase is produced by actively
growing haemolytic streptococci of the Lancefield's groups A, human
C and G (Tillett, 1952), is readily soluble at pH's both acid and alkaline
to the isoelectric point (4.7-5.0) and is stable over a wide pH range.
At a pH of more than 9.0, however, it undergoes irreversible inactivation.
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The action of SK appears to be restricted to plasminogen activation.
It is not itself proteolytic for casein nor does it act on synthetic
substrates (Sherry and Alkjaersig, 1957). However, the activator
formed by the interaction of SK and the human serum factor seems
to be a proteolytic enzyme (Alkjaersig, Fletcher and Sherry, 1958 a).
A potent preparation of streptokinase-streptodornase "Varidase" is
now marketed.
2. Staphvlokinase. Strains of staphylococci vary in their production
of this enzyme. Staphylokinase differs from SK because it can
activate the plasminogen of many animal species (Gerheim and Ferguson,
194-9; Cliffton and Cannamela, 1951; 1953).
C. Miscellaneous activators:
1. Chloroform and other organic solvents. These were the earliest
known activators of the fibrinolytic system. In 1889 Denys and Marbaix
found that a thermolabile proteolytic agent developed in serum after the
addition of chloroform, ether or thymol. They concluded that a
proteolytic enzyme present in serum was normally inhibited by some other
substance which chloroform removed or destroyed and Ghristensen (194.6)
agreed with these findings. Chloroform activation is a slow process
(Baumgarten, Cole, Richard and Smith, 1957) which only occurs within a
narrow range of its concentration since it may otherwise denature
plasminogen.
2. Peptone. Nolf (1905) produced an increased fibrinolytic activity
in hepatectomized dogs by the intravenous injection of peptone. It has
been recently shown that the treatment of guinea pig serum by peptone
produces a plasminogen activator and also a proteolytic enzyme in the
euglobulin fraction (Ungar and Mist, 1949). Olesen (1957) using the
fibrin plate method obtained further evidence of the activator action
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of peptone, and Astrup and Olesen (1957) partially purified the factor
responsible for this action.
3. Urea and aromatic derivatives and hvdrotropic substances. von Kaulla
and Smith (1961) have observed that activity similar to that exerted by
3K can be brought about by certain urea derivatives (but not by urea itself),
von Kaulla (1962) later found that hydrotropy is a common denominator of
the active urea derivatives and of some other aromatic compounds which
activate the fibrinolytic system in vitro.
Mechanism of Plasminogen
Activation.
In their comprehensive review on fibrinolysis, Sherry, Fletcher and
Alkjaersig (1959) state that "It has been demonstrated that the kinetics
of activation of plasminogen by urokinase, streptokinase and trypsin are
consistent with a first order enzymatic reaction (Alkjaersig, Fletcher
and Sherry, 1958 a). Certain features are common to all these activations,
including the autocatalytic activation of plasminogen: l) significant
quantities of acid-soluble nitrogen, tyrosine and carbohydrate are
released from plasminogen during the activation; 2) the activation is
mediated by an enzyme capable of splitting arginine and lysine esters; and
3) the latter act as competitive inhibitors to plasminogen activation. Thus
the activation process appears to include a proteolytic step in which lysine
and/or arginine bonds are split. However, the existence of two general
types of activation is suggested by the observation that differences exist
between the activation occurring in the presence of certain activators
(urokinase and streptokinase), and that produced by other activators
(trypsin and plasmin). The former activation occurs in the presence of
plasmin inhibitors, is rapid, and results in a plasmin apparently
physico-chemically distinct from that obtained with trypsin or plasmin,
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where activation is relatively slow and readily influenced by the presence
of plasmin inhibitors (Alkjaersig, Fletcher and Sherry, 1953; 1953 a)".
Plasmin.
Plasmin is the active proteolytic enzyme produced by the action of
activator(s) on plasminogen. Plasma, serum and possibly platelets
carry antiplasmins (Johnson and Schneider, 1953; Stefanini and Murphy,
1956; Sherry and Alkjaersig, 1957) normally in a considerable excess,
and provided, as is the case under physiological circumstances, plasmin
formation does not take place more quickly than plasmin neutralization,
no free plasmin appears in the circulation (McNieol, 1962).
Plasmin is most active at neutral pH but its isolation and
purification has been difficult because of its instability at this pH.
The present progress towards the preparation of pure plasminogen is
essential as a means of preparing pure plasmin. At present, production
of plasmin has been from plasminogen preparations either spontaneously
in the presence of stabilizing agents like glycerol-buffer (Alkjaersig,
Fletcher and Sherry, 1953), or by the use of specific activators, such as
SK. Using the latter method Troll and Sherry (1955) activated plasminogen
with SK and precipitated the enzyme at pH 2.0. Fishman and Kline (1956)
carried the process a step further by alcohol fractionation of the product of
SK activation. It is now, however, thought that the activity ascribed to
plasmin in these preparations is probably due to the contaminating
activators. Physico-chemical studies suggest that the sedimentation constant
and molecular size of plasmin depend on the mode of activation (Shulmai,
Alkjaersig and Sherry, 1953).
Plasmin hydrolyses such naturally occurring proteins as fibrin,
fibrinogen, factors V and VIII (Ferguson, 194-9; Johnson, Seegers and
Braden, 1952; Sherry, Titchener, Gottesman, Wasserman and Troll, 1954;
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Soulier, Alagille and Larieu, 1956; Gliffton, 1957; Coon and Duff, 1958;
Koller, 1961), some of the components of complement (Alagille and Soulier,
1956), A.C.T.H., growth hormone and glucagon (Mirsky, Perisutti and Davis,
1959)= Other protein substrates for plasmin are casein (Remmert and
Cohen, 194-9; Christensen, 1954 a) gelatin (Christensen, 1945), beta
lactoglobulin (Christensen, 1954) and protamine complexes (Kjeldgaard
and Ploug, 1957).
There is no parallel correlation between the fibrinolytic, the
fibrinogenolytic and other proteolytic activities of plasmin. Ratnoff
(1953; 1955) has noted that whereas plasmin digests fibrin and fibrinogen
at equal rates which accords with Christensen's observations (1945), he
found that fibrin is more rapidly destroyed than fibrinogen during spontaneous
activation in human blood and after the addition of SK. Ratnoff suggests
that plasminogen activation is enhanced by the clotting mechanism, possibly
through an effect of the fibrin surface. This is substantiated by the
findings of Gelander and Guest (1957). According to McNicol (1962),
inhibitory mechanisms largely restrict the action of plasmin to the
digestion of fibrin in vivo.
As early as 1887 Green made the fundamental observation that once
fibrin is 'dissolved' it could not be coagulated by thrombin. But even
now, the exact composition of the products of fibrin and other protein
degradation resulting from the action of plasmin is not known. Plasmin,
however, degrades fibrin into a number of peptides and amino acids. There
is evidence that plasmin splits proteins at arginine and lysine bonds,
in that synthetic esters of the basic amino acids arginine and lysine act
as excellent plasmin substrates and as competitive inhibitors of the
proteolytic and fibrinolytic activities of the enzyme (Troll, Sherry and
Wachman, 1954).
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Although similarities in the modes of action of plasmin and thrombin
have been described (Seegers, 1952; Ronwin, 1956), the separate identity of
these two enzymes has been established along many lines (Sherry, Fletcher
and Alkjaersig, 1959).
Defective fibrin polymerization.
Recently, Fletcher, Alkjaersig and Sherry (1962) have shown that
patients under treatment with plasminogen activators may develop a
coagulation defect similar to that observed in patients who 'spontaneously'
develop states of 'pathological plasma proteolytic activity' or
'hyperplasminaemia'. According to these authors, the major coagulation
defect in these instances, is due to the presence of the products of
proteolysis formed from fibrinogen or fibrin and circulating in the plasma.
The two main features of these anomalies are an increase of thrombin
time and a macroscopically apparent defect in clot appearance and
character. The biochemical lesion responsible for these defects has
been termed "defective fibrin polymerization" by Alkjaersig, Fletcher and
Sherry (1962). It is not yet known how this phenomenon can be
reconciled with the work of Niewiarowski and Kowalski (1958), Niewiarowski,
Kowalski and Stachurska (1959) and Kowalski (i960) where it was held that
such anticoagulant activity derived from the degradation products of fibrinogen
was due to inhibitors of blood coagulation for example antithrombin VI,
another product of fibrinolysis.
Inhibitors (antiplasmins).
The assumption of the presence in the circulation of inhibitors of
fibrinolysis has been drawn from the observations of Denys and Marbaix (1889)
that the proteolytic activity which develops after the addition of chloroform
to serum is due to the removal or destruction of some inhibitory substance
in the serum. This has been supported by Hahn who in 1897 noticed an
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antitryptic property of serum.
Antiplasmins have been found in the blood of many animals as well
as in that of man (Guest, Daly, Ware and Seegers 1948 a). It has been
shown by Bundy and Mehl (1958) that there is no sex difference in the
level of serum trypsin inhibitors. The inhibitory power of plasma is markedly
in excess of its plasmin activity (Noman, 1958; McNicol, 1962). There
has been much argument about the possible existence of two or more serum
antiplasmins (Ratnoff, Lepow and Pillemer, 1954-1 Norman, 1357; 1958;
Norman and Hill, 1958). Shulman (1355) isolated and partly characterized
an interesting inhibitor of proteolytic activity from both urine and
plasma.
Plasmin inhibitors have also been reported in many tissues (Cohen
and Warren, 1961) and in platelets (Johnson and Schneider, 1953), but
overall there have been very few such investigations, a fact which applies
to inhibitors of all kinds.
f
Stefanini and Dameshek (1955) found that cortisone promptly reduced
the activity of serum fibrinolysins and Ungar and Damgaard (1951) showed
that A.C.T.H. and cortisone significantly increased the antifibrinolytic
activity in the intact normal animal but that there was no such increase
following the injection of A.C.T.H. or cortisone into splenectomized
guinea pigs. The plasmin inhibiting properties of A.C.T.H. are
discussed by Cohen and Warren (1961).
The level of antifibrinolysins is increased in nephrosis (Jacobsson,
1955), in pernicious anaemia and in pneumonia (Guest, Daly, Ware and
Seegers, 1948), in platelet-rich plasma (Stefanini and Murphy, 1956)
and in plasma following fatty meals (Greig and Runde, 1957).
Controversy surrounds the nature and number of plasma components
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capable of inhibiting plasmin activity. Mlstone (194-1) found,
antiplasmin activity in the pseudoglobulin fraction and Macfarlane
and Pilling (194-6) found it to be in the supernatant of the
euglobulin precipitate of low ionic strength and at pH 5.3. Evidence
how now accumulated that inhibitors can be recovered from the
albumin (Lewis, Walters, Didisheim and Merchant, 1958; Phillips and
Skrodelis, 1958; Cherry, Adamsons and Phillips, 1961), beta one
(Lewis et al.. 1958), alpha one and alpha two globulins (Bundy and
Mehl, 1958; Lewis et al., 1958; Cherry, Adamsons and Phillips,
1961). By Cohn fractionation it has been demonstrated that
different plasmin inhibitors can be separated from fractions 17
and 7 (Grob, 194-9; Norman, 1958).
Inhibitors of the fibrinolytic system fall into t\ro main categories,
those acting upon (i) the activation process (inactivators) and (ii),
active plasmin, which can be aptly called antiplasmins.
i. Inhibitors of the activation -process: The occurrence of
naturally occurring activator inhibitors has been proved (Lewis and
Ferguson, 1951; Mullertz, 1956; 1957). Mullertz (1957) noted that a
crude sample of bovine globulin inhibited the activation of bovine
plasminogen by SK activated human globulin.
ii. Inhibitors of plasmin (antfplasmins). It has been shown by
Sawyer, Fletcher, Alkjaersig and Sherry (i960) that plasmin is almost
immediately inactivated when added to plasma, but due to technical
difficulties of assay?many authors intending to measure antiplasmins
have measured antitryptic activity instead (Christensen and Macleod,
194-5; Christensen, 194.6; Cliffton, 1952; de Leeuw, Wright, and Morton,
1953). It is now known that antiplasmin and antitryptic activity of
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plasma do not parallel one another which makes this approach
unsatisfactory (Shulmaa, 1952; 1952 a; 1952 b).
Synthetic Inhibitors of the Fibrinolytic System
In the majority of reports, the differentiation between substances
acting as activator inhibitors and those acting directly on plasmin
(antiplasmins) has been unsatisfactory since the methods used have
been incapable of distinguishing between them.
Epsilon amino caproic acid (E.A.G.A.), a structural analogue of
lysine, was originally described as a plasmin inhibitor. It has now
been shown that E.A.C.A. is a far. more potent inhibitor of plasminogen
activation than of plasmin (Ablondi, Hagan, Philips and De Renzo, 1959J
Ablondi and De Renzo, 1959; Alkjaersig, Fletcher and Sherry, 1959).
E.A.G.A. inhibits plasminogen activation by SK and by urokinase
competitively. It inhibits trypsin and autocatalytic plasmin activation
in a noncompetitive manner.
Quaternary amines, lauryl amine and E.A.C.A. which act as plasmin
inhibitors at high concentrations, potentiate the action of plasmin at
very low concentrations on a number of substrates (Astrup and Alkjaersig,
1951; 1952; Alkjaersig, Fletcher and Sherry, 1959). Sodium chloride,
while inhibiting the activation of crude bovine plasminogen by SK and
human globulin activator, does not inhibit the activation of human
plasminogen (Cole and Mertz, 1961 a).
Other synthetic inhibitors include numerous organic substrates, dyes
and related compounds (Geiger, 1952), heparin and similar substances
(Astrup and Alkjaersig, 1952; von Kaulla and McDonald, 1958), basic
amino acids (Mullertz, 1954-), their polymers (Ginsburg, de Vries and
Katchalski, 1952) and esters (Troll, Sherry and Wachman, 1954-), methylamine
and urea (Norman, 1957).
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Inorganic ions (Ronwin, 1962) particularly the heavy metals
(Kowalski and Latallo, 1956), will also inhibit or denature plasmin.
Trypsin inhibitors such as pancreatic trypsin inhibitor (Christensen
and MacLeod, 1945), soya bean (Christensen and MacLeod, 1945; Astrup
and Alkjaersig, 1952), and toxic phosphorus compounds (Mounter and
Shipley, 1958) also inhibit plasmin action.
Use of Fibrinolytic Agents in the
Management of Thromboembolic Conditions.
One of the chief interests in fibrinolysis and in fibrinolytic
agents is the possible use of these latter substances in thromboembolic
diseases and some inflammatory conditions which do not produce necrosis
of tissues. Progress in the field has been slow, but, as Koller
(1961) points out "Although fibrinolytic therapy was virtually started
in 1933 with the discovery of the fibrinolytic effect of streptococci,
27 years later fibrinolytic treatment is still in a preliminary stage.
However, the purification of heparin needed 20 years and only 30 years
after its discovery was it used on a large scale. Therefore, there is
no reason to be. concerned about the relatively slow advance of our knowledge
in fibrinolytic therapy and the many difficulties encountered in its
realization". Many satisfactory results have been achieved but progress
has been hampered by many controversial findings. In fact a depressed
fibrinolytic activity in patients with thrombotic diseases, with
atherosclerosis and following fatty meals (Nestel, I960; Tilliman,
O'Neal, Thomas and Hixon, i960) which have formed bases for thrombolytic
treatment, has been denied by Hougie and Ayers (i960), Blix (1961) and
by Berry (1962). The observations of Buckell and Elliott (1959)
that there is less flexibility of the fibrinolytic system with advancing
age may prove a useful means of research into this problem.
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Many fibrinolytic agents have been investigated clinically.
Streptokinase has been widely used (Koller, 1961). In a recent leading
article (Brit.med.J., 1393, May 19th, 1962) much has been said about
urokinase. The active enzyme, plasmin, has also been tried (Cliffton,
I96I). Other agents include pyrogens (von Kaulla, 1958), fungal agents
(Karaca, Stefanini. .and Mele, I962), nicotinic acid (Weiner, Redisch and
Steele, 1958), complamin which is a combination of nicotinic acid and
theophylline (Koller, 1961), urea derivatives (von Kaulla and Smith,
I96I) and an enzyme derived from Pseudomonas fluorescens (Adamis, 1961).
Difficulties' with thrombolytic agents are met with in control
of dosage. Febrile and allergic reactions to the drugs are now
infrequent since purification methods have been improved. The develop¬
ment of antibodies towards SK after prolonged therapy and after acute
haemolytie streptococcal infections is a potential hazard (Blix, I96I a).
In experimentally produced high levels of blood fibrinogen in dogs ,
an increased resistance of clots to lyse has been observed (Bang,
Freiman and Cliffton, i960).
Contraindictions to fibrinolytic therapy include defective blood
coagulation especially where there is depressed liver function and where
there is a deficiency of factors V and VIII and of fibrinogen.
In general, it may be said that well controlled fibrinolytic therapy
is safe and produces less haemorrhages than some anticoagulants. This
safety has been further ensured by the availability of E.A.G.A. which
is a well tolerated, drug.
Evaluation of the Methods of Assay of the Fibrinolytic System.
The process of fibrinolysis is complex, involving an interaction
between the fibrin clot and the serum with which it is in contact. The
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main participants in this reaction are plasminogen, proactivator and
activators, plasmin, plasmin inhibitors and fibrinogen. The complexity
of the system, the lack of knowledge concerning it and the inability
to isolate the (hypothetical) constituents have all contributed to the
difficulties in formulating assay methods and those in use have marked
limitations. Preparations of fibrin and fibrinogen used as physiological
substrates are invariably, significantly and seriously contaminated
with plasminogen due to the tremendous affinity of the latter for fibrin and
fibrinogen. Synthetic substrates such as arginine and lysine esters
have been tried, but they lack specificity and other non-plasmin serum
enzymes are capable of hydrolysing them (Troll, Sherry and Wachman, 1954-).
The effect of different reagents used on the fibrinolytic mechanism may
produce variable and fallacious results which depend upon the method
of assay used.
The "fibrinolytic activity" of plasma has been assayed on four
main line s
I Depending on (l) its fibrinolytic properties (Loomis, George and
Ryder, 194-7; Astrup and Mullertz, 1952; Shulman, 1952; Fletcher,
1954- a; Fearnley, Balmforth and Fearnley, 1957) (2) its fibrlnogenolytic
properties (Mullertz, 1952).
These tests include clot lysis times of whole and of diluted
blood (Chakrabarti and Fearnley, 1962), of whole and of diluted plasma
(Maefarlane, 1937, Swan, I96I), tests based on the ability of serum to.
lyse normal clots (Male, I962), the use of fibrin and plasma plates
(Astrup and Mullertz, 1952; von Kaulla and McDonald, 1958) and. the
euglobulin lysis time (Macfarlane and Pilling, 194-6; Biggs and Macfarlane,
1962). Tests have also been used which measure the degree and pattern
of standard clot lysis by the estimation of the amount of residual clot
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based on its tyrosine content (Bidwell, 1953), the use of fluorescein
labelled fibrin (Pappenhagen, Koppel and Olwin, 1962), of .isotopically
labelled human plasma, clots (Sawyer, Fletcher, Alkjaersig and Sherry,
i960) and by throrabelastography (Hartert, 1951; de Nicola and Mazzetti,
1955; von Kaulla, 1957).
II. Based on its proteolytic properties. Substances used have
included gelatin, azocoll, protamine complexes, urea-denatured haemoglobin
and chiefly casein (Remmert and Cohen, 194-9; Christensen, 1954- a;
Kaplan, 1954-; Kline and Fishman, 1961).
III. Utilisation of synthetic substrates such as lysine and arginine
esters (Schultz, Moorman, Matoush and Lincoln, 1957; Lassen, 1958;
Roberts, 1958)
IV. Immunochemical analysis (Hagan, Ablondi and De Renzo, I960).
The simplest way to measure fibrinolytic activity is by the
observation of the whole blood clot lysis time. Somewhat more complex
but similar are methods determining, l) the diluted whole blood clot
lysis time (Chakrabarti and Fearnley, I962), the whole plasma arid diluted
plasma clot lysis times (Macfarlane, 1937, Swan, 1961) and the ability of
serum to lyse normal clots (Miale, 1962)0 These methods are valuable
for detecting markedly enhanced fibrinolytic activity, but are inadequate
for measuring low levels of such activity often because of the very long
lysis times. The end point was once not reached for more than ten days
(Swan, I96I). In addition,dilution may artifically create 'fibrinolytic
activity' since Fearnley and Ferguson (1958) claim that an undiluted
clot does not liquefy.
Fibrin and Plasma plates.
The fibrin plate test has been widely used (Astrup and Mullertz,
1952; von Kaulla and McDonald, 1958) whereby either a fibrinogen
37
solution or plasma is clotted in a Petri dish, inoculated with the
material to be tested and incubated overnight. The area of lysis
gives an estimate of 'fibrinolytic activity' of the substance tested.
The fibrin plate is an excellent test for high levels (Douglas, 1962)
but not for low levels of activity (von Kaulla and Schultz, 1958).
The bovine fibrin usually used as substrate contains bovine
plasminogen as a contaminant and measures therefore active fibrinolytic
enzymes which at the most are only present in tra.ce amounts in plasma,
as well as activators. The fibrin plate is therefore considered to
measure the activator content. In order to estimate only the level
of plasmin under investigation and not that due to activation of
plasminogen contained in the substrate as well it has been suggested
that the plasminogen content of the fibrin plate should be destroyed by
heating before it is used in this test (Lassen, 1953; Mullertz and Lassen,
1953; Mullertz, 1957). Fibrin plates can also be used to assess
streptokinase activity (Biggs and Macfarlane, 1962).
Plasma Buglobulin Lysis Time.
Macfarlane and Pilling (194-6) first suggested the use of this
method which is now known to be based on the fact that the plasma euglobulin
(which together with some of pseudoglobulin I form the gamma globulins)
(Hoffman, 1955) contain the essential clotting factors as well as
plasminogen and plasmin (Cherry, Adamsons and Phillips, 1961). The
plasma is first diluted so that the antiplasmins which are associated
with albumin and alpha globulin fractions (Cherry, Adamsons and Phillips,
1961) remain in solution when the euglobulin fraction is precipitated by
acidification to a low pH. The precipitated euglobulin is then
redissolved and clotted and then invariably undergoes lysis, the time
for which even under normal conditions is shcFt enough to give a rapid result.
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The method can. be used even when heparin is present and will readily
detect weak fibrinolytic activity. This method has the advantage of
requiring neither special equipment nor a high degree of skill. It has
been claimed by Buckell (1958) that the type of anticoagulant used in
blood withdrawal affects the euglobulin lysis time (E.L.T.), the
maximum fibrinolytic activity being found in citrated specimens, whilst
specimens taken into heparin and sequestrene (E.D.T.A.) showed less
activity. This illustrates the importance of standardised procedures.
The E.L.T. measures mainly the activators, the contribution by
plasmin being very small. The significant, although imprecise,
correlation between the isotopically - labelled human plasma clot assay
(a very elaborate technique) and the plasma euglobulin lysis time
technique reinforces the validity of this latter assay method (Sawyers,
Fletcher, Alkjaersig and Sherry, i960). A micro-method for E.L.T.
assay suggested by Copley, Niewiarowski and Marechal (1959) may prove
to be very useful. The E.L.T. has been considered the best of the
simpler methods of assay (Douglas, 1962) and has been recommended by
many authors (Wintrobe, 1961; Biggs and Macfarlane, I962) for the
estimation of the "fibrinolytic activity". The use of the method in
the control of thrombolytic therapy (Douglas, 1962; Poller, 1962) gives
it a special importance among other tests.
Clot Tyrosine Method.
A method relating the lysis pattern of a series of clots incubated
for varying intervals of time and measuring the amounts of residual clots
by their tyrosine content has been described (Bidwell, 1953; Biggs and
Macfarlane, I962). von Kaulla and Schultz (1958) do not regard the method
as a practical one from the clinical point of view and in this work the
results were not found to be reproducible on duplicate assays.
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Fluorescein - Labelled Fibrin.
The technique of assay using fluorescein-labelled fibrin
(Pappenhagen, Koppel and Olwin, 1962) is still in its infancy, but
shows promise.
Isotopically - Labelled Clots
131In the methods using I-labelled human plasma, clots are formed
from aged human plasma enriched with human plasminogen and containing
131trace quantities of I-labelled bovine fibrinogen. These are incubated
in the material to be tested for a standard time. The residual clots
are then separated by filtration and the radioactivity of the total
filtrate determined. Sawyer et al.. (i960), using this method found
that plasma obtained from non-stressed normal adults showed activator
activity which varied as a result of stress and disease. They found
no sex difference, no correlation with age, no clear evidence of diurnal
variation and no striking daily fluctuations in the activity among the
adult population they studied. The method is too elaborate and expensive
for routine use.
Thrombelastography.
Thrombelastography as introduced by Professor Hartert of Heidelberg
University (1951), permits continuous visual and kymographic observation
of all phases of coagulation, including fibrinolysis. The measurement
is automatic and is based on the principle of determining the elasticity
of the fibrin clot. Thrombelastography can be done on intact whole
blood, is rapid and reliable, even when the fibrinolytic process takes
a few minutes or several Hours for its completion (de Nicola and Mazzetti,
1955; von Kaulla, 1957; von Kaulla and Schultz, 1958).
4-0
Caseinolytic Assays.
Among proteolytic assays available, the most popular is the
caseinolytic one which many considered to be best routine method of
estimating plasminogen (Douglas, 1962), for though plasminogen and
plasmin are measured together by this method, the amount of plasmin
in normal plasma is negligible. Sawyer et al., (i960), however, state
that the 'thrombolytic activity' and plasma 'proteolytic activity' are
independent of one another.
The method originally introduced by Remmert and Cohen (194-9), has
been widely adopted (Christensen, 1954- a; Kaplan, 1954-; Norman, 1957).
The plasma is first acidified to prevent coupling of the major portion
of the plasmin with antiplasmin which would result in loss of plasminogen.
The plasminogen is then converted to plasmin by SK in which form it can
be measured by hydrolysis of casein and the surplus undigested casein is
then precipitated with trichloracetic acid and the trichloracetic
acid-soluble tyrosine estimated by spectrophotometry.
Use of Synthetic Substrates.
The use of synthetic substrates by Schultz, Moorman, Matoush and
Lincoln (1957) and by Roberts (1958) has proved unsatisfactory in the
investigation of physiological fibrinolysis, probably because fibrin
due to its strong adsorption of fibrinolytic factors, is a much more
susceptible substrate and thus reacts when other substrates remain
•unchanged (Biggs and Macfarlane, 1962). Furthermore, these synthetic
substrates are not specific for plasmin and non-plasmin esterase activity
may produce false assay values. Schultz et al.. (1957) obtained
unsatisfactory results using lysine ethyl ester and tosylarginine methyl
ester as substrates for the determination of the fibrinolytic activity of
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normal human plasma and this was confirmed by von Kaulla and Schultz
(1958).
Cole and Mertz (1961) demonstrated that the fibrinolytic activity
of both bovine and human plasminogen preparations parallels their
caseinolytic activity in a linear relationship but that there was no
such relationship between the fibrinolytic and esterolytic activities.
Immunochemical Method.
An immunochemical method based on the Ouchterlony agar gel diffusion
technique using as antibody a serum prepared from rabbits which had
been injected with an extract of fraction III was used by Hagan, Ablondi
and De Renzo (i960). It is possible that when the antigen has been
isolated in a pure form this method may be valuable.
Assays of Inhibitors.
The difficulty in assaying various components of the fibrinolytic
system is illustrated par excellence by the difficulty in assaying
antiplasmin(s). This has been due to difficulty in preparing potent
plasmin free from plasminogen and from activator and also due to the
lack of agreement on an international plasmin unit. Plasminogen
preparation and activation(Fishman and Kline, 1956; Kline and Fishman,
1961 a) is a time-consuming procedure. We have used a ready made active
preparation 'Thrombolysin' with satisfactory results. Techniques
have been used to determine antifibrinolytic properties based on the
capacity of the plasma or serum under test to block the action of plasmin
in a fibrinogen-thrombin clot indicator system. Bozzo, Piomelli and
Schettini (1956) used a fixed amount of plasmin in varying dilutions
of the serum under test, whereas, Biezenski (i960) added his plasmin
in various dilutions to fixed amounts of the test serum. Since serum
and plasma contain the same amount of antifibrinolysins (Grob, 194-9;
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Biezenski, i960) either can be used. The second method has been
successfully used in this study. Biezenski found the level of
antifibrinolysins to be stable in normal individuals.
Methods based on anticaseinolytic properties estimate either (1)
the difference between caseinolytic activity of plasmin before and
after incubation with the inhibitory substance (Sherry, Lindemeyer,
Fletcher and Alkjaersig, 1959)? or (2) the differences in caseinolytic
activity of activated and inactivated euglobulins (Berry, 1962),or (3)
the difference in activity of whole serum and of euglobulin fraction
(Quie and Wannamaker, i960). All available methods of inhibitor
estimation are at the best semi quantitative.
Rapid Fibrinogen Determinations (Hardisty, 1958)
Rapid fibrinogen assays may be required in cases of excessive
fibrinolysis and/or in "hyperplasminaemia". The standard methods
of plasma fibrinogen estimation in which a chemical determination of the
protein content of the fibrin clot is used are too time-consuming to be
of immediate practical value in such cases, and are inaccurate at fibrinogen
levels of less than 35 mg. per 100 ml. These methods, which will not
be considered here, may be used to confirm results obtained by more rapid
procedures.
For rapid determination of fibrinogen for example in the acute
defibrination syndrome the following tests are useful.
1. Whole blood clotting time.
2. Thrombin clotting time of plasma.
3. Turbidimetric fibrinogen assay.
(l). In the clotting time test, if a solid clot forms within ten
minutes, there is no significant deficiency of fibrinogen. Fibrinogen
levels beloxir 100 mg. per 100 ml. result in the formation of small friable
43
clots and possibly in some prolongation of the clotting time. If the
fibrinogen level falls below 30 mg. per 100 ml., no visible clot may
be formed.
(2). Thrombin Time. A small friable or filamentous clot, usually
associated with a prolonged clotting time, denotes fibrinogen deficiency.
Complete failure of clot formation in plasma denotes a fibrinogen level
below about 10 mg. per 100 ml.
(3). Turbidimetric Assay. Fibrinogen is precipitated from plasma
using ammonium sulphate in a final concentration of 13 per cent. The
fibrinogen concentration of the plasma is determined from photometric
readings by reference to a standard calibration curve.
Recently a rapid immunological test (Fi test, Hyland Laboratories,





TECHNIQUES USED IN THE INVESTIGATION







The technical methods employed in these cases have previously
been reported in the literature but have been modified slightly in
most cases.
(1) Heated Fibrin Plate Technique.
Reagents.
1. 0.4% bovine fibrinogen (Armour) in veronal acetate buffered
saline, pH adjusted to 7.4 if necessary with N/lO NaOH or N/lO
HG1, and kept frozen at - 20°C.
2. Veronal acetate base: 9*714 G. sodium acetate trihydrate, 14.714 G.
sodium diethyl barbiturate; made up to 500 ml. with distilled water
(D.W. )
3. Veronal acetate buffered saline : 25 ml. veronal acetate base
(see Reagent No. 2 above), 25 ml. N/lO hydrochloric acid, 450 ml. normal
saline; pH adjusted to 7.4 ± 0.05 (glass electrode).
4o Thrombin (Maw) : 200 National Institutes of Health (N.I.H. ) units
per ml. in buffered saline.
5. Bromothymol blue: 0.04% in 95% ethyl alcohol.
6. Flat-bottomed Petri dishes 9 cm. diameter carefully selected for
a uniform flat base; conical flasks about 30 ml. capacity and filter
paper.
Method.
To 10 ml. of fibrinogen solution in a conical flask add 0.1 ml.
thrombin and quickly mix the contents and then pour into a Petri dish
avoiding contamination by air bubbles. After clotting has occurred
incubate the plate at 37°G. for 10 minutes. Apply a damp filter paper
to the inside of the topcover of the Petri dish and heat the plate at
85°C.in a hot air oven for 45 minutes. After cooling to room temperature,
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inoculate the plate with a standard drop (0.03 ml.) of the test material.
Duplicate this on the same plate, then incubate the plate overnight (about
18 hours) at 37°C. Keep the plates absolutely horizontal throughout.
Outline the lytic areas by a drop or two of bromothymol blue (Soardi,
Stefanini, Stump and Marin, i960). See figure 3 of the fibrin plate.
The application of local sodium hydroxide i^hich the last authors recommend
has proved unsatisfactory in this study by causing rapid non-specific
digestion of the fibrin.
The results are expressed by calculating the areas of lysis
which, however, are not related to the enzyme concentration in a simple
arithmetical ratio but the logarithms of the areas of lysis are directly
proportional to those of the plasmin concentrations. This is shown in
figure 4 where the test has been carried out on serial dilutions of a
solution of plasmin 'Thrombolysin', Batch I\T°. G-1423 in distilled water.
A hundred per cent solution is one that contains 150 mg./ of the enzyme.
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Normal areas of lysis for the euglobulin fractions of plasma (see E.L.T.)
2
are 20 to 50 mm and measure plasma plasmin activity.
Figure 4- Application of heated fibrin plate for the study of
plasmin 'thrombolysin' activity. A hyperbolic
curve is obtained by plotting the digested fibrin
area in mm against plasmin dilution expressed as
reciprocal. The curve is changed to a straight
line when the lysed area and plasmin concentration
per cent are both expressed logarithmically.
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(2). Plasma Euglobulin Lysis Time (E.L.T.)
Reagents
1, Plasmaj This is prepared from a mixture of nine parts of whole
blood with one part of 3.8% sodium citrate (B.P) solution. Plasma
processing may begin immediately or the specimen may be kept for few
days at - 20°Co Standardization of the procedure is essential.
2. One per cent acetic acid.
3c Wash solution; 4-50 ml. D.W. + 25 ml. normal saline + 1% acetic
acid to bring the pH to 5.2.
4-c Veronal acetate buffered saline : (see fibrin plate method)
5. ¥i/L0 calcium chloride.
6. Scrupulously clean test tubes, pointed glass rods, pH indicator
paper and distilled water.
Method
The test is done in duplicate. To 0.5 ml. plasma, 9 ml. of
distilled water are added and the pH brought to 5.2 with 1% acetic acid.
The precipitate is kept at 4°G. for 20 minutes, centrifuged at 3,000
r.p.m. for 5 minutes and washed while undisturbed, with wash solution.
The inside of the tube is carefully wiped dry and the precipitate
dissolved completely in 0.5 ml. veronal acetate buffered saline stirring
with a glass rod. After two minutes in a 37°G. water bath, the dissolved
euglobulin solution is clotted with 0.5 ml. W/UO calcium chloride. For
heparinized specimens from patients submitted to open-heart surgery on the
heart-lung machine, the precipitate is dissolved in one ml. buffered saline
and clotted with 0.05 ml. thrombin solution (Thrombin, Topical, Parke, Davis
& Co)?200 N.I.H. units/ml. of distilled water. The basic pattern of the
euglobulin lysis is that of a slow onset followed by increasing disintegration
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speed of the coagulum with paracoagulation (Derechin, 1955) occurring
at intervals. Complete lysis of the clot(s), x^hich may be quite
unheralded is expressed in minutes and is the euglobulin lysis time. In
our hands values from 120 to 330 minutes with rarely a prolongation of this
upper limit have been found in normal adult individuals on morning
specimens. On afternoon specimens, normal values as low as 80 minutes
have been encountered. This can be expressed as a rate (Buekell, 1958)
using the equation:
Rate = 1000
lysis time in minutes
Maximum normal rates of 8 and 12 for morning and afternoon specimens
respectively have been obtained.for overall fibrinolytic and/or activator
activity.
(3) Caseinolytic Assay (Biggs & Macfarlane, 1962).
Reagents
1. Phosphate solution: 0.1 M disodium hydrogen orthophosphate in 0,9%
NaGl, pH 7.6.
20 5% easein^in phosphate solution. Hammersten casein (Hagan,
Ablondi and De Renzo, I960) and Pfanstiehl casein (Bundy and Mehl, 1958)
have been used with success by the respective authors.
3. N/6 NaOH
4-. 10% trichloracetic acid.
5. Streptokinase 2000 units/ml. phosphate solution (Varidase-Lederle).
60 N/6 HC1
7o Citrated. plasma (see euglobulin lysis time p. 4-7)
Method.
To 0.5 ml. plasma is added 0.5 ml-N/6 HC1 and the mixture kept at
room temperature for 15 minutes, after which 0.5 ml. of N/6 NaOH is added
* (Locally purified casein according to the method of Reromert and Gohen (.194-9)
has been made and supplied by the Blood Transfusion Service, Edinburgh).
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followed by 1 ml, of 0.1 M phosphate solution, 0.5 ml, SK solution
and 2 ml. of 5$ casein. The mixture is incubated at 37°0. After
2 minutes 2.5 ml. is withdrawn from the incubated mixture and added
to 2.5 ml. of 10$ trichloracetic acid (tube A). After 10 minutes
of incubation of the precipitate in tube A at 37°G0 (to ensure complete
precipitation of undigested casein and possibly large polypeptide
molecules) the contents are filtered through a Whatman No.l filter
paper. After 62 minutes of incubation of the original mixture, 2.5 ml.
of 10$ trichloracetic acid is added to the remaining 2.5 ml. of the
mixture and the precipitate filtered after a further 10 minutes incubation.
The difference in degree of caseinolyfcic breakdown in both solutions
A & B is measured as a trichloracetic acid - soluble tyrosine moiety
in a Unicam SP 500 spectrophotometer at a wavelength of 280 millimicrons.
The caseinolytic activity is arbitrarily expressed as the increase in
optical density of the trichloracetic acid filtrate after 60 minutes
incubation, multiplied by 1000. Normal values are 239 - AA3 units of plasmino-
gen. , .
(A). Assay of Antifibrinolytic Activity.
Reagents.
1. Fibrinogen solution: Human fibrinogen as Cohn fraction I (supplied
by Blood Transfusion Service, Edinburgh) is used in a concentration
of 250 mg.$ in veronal acetate buffered saline (see under fibrin plate)
but is stored in a tenfold concentration at - 20°C. and diluted to the
required concentration immediately before use.
2. Thrombin (Maw): 10 N.I.H. units per ml. distilled water.
3. Plasmin solution: "Thrombolysin" is used in a predetermined
strength which just lyses the clot at minimal plasmin dilution in the
indicator system and this concentration is determined afresh for each
new batch of plasmin solution used. For the batch we used (C-14-23)
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this was found to be on an average 150 mg.% in distilled water. Plasmin
solution is stored in 2.5 ml. amounts at - 20°C. and is stable for a
few months.
4-o Plasma: Citrated plasma (see E.L.T. p.A7 ) is diluted l/20 with
buffered saline immediately before use.
Method.
A series of 12 dilutions ranging from l/2 to l/2% of the plasmin
solution in use is made in buffered saline as the diluent. To each
of a set of 12 tubes is added 0.1 ml. of the plasmin dilution and 0.1
ml. of the diluted test plasma. The tubes are then incubated at
37°C. for 12 minutes and 0.2 ml. of fibrinogen solution and 0.2 ml.
of thrombin solution are then added in quick succession. When clot
formation is complete the mixture is left undisturbed at 37°G. for
exactly 30 minutes. Positive and negative controls are set up, the
former of plasmin in buffered saline and these tubes should all show
lysis and the latter of buffered saline in plasma and in these tubes
there should be no lysis.
The result is expressed as the titre at which the lowest plasmin
dilution fails to lyse the indicator clot. The results can also be
expressed as a percentage of normal, calculated by comparing the titre
obtained using the solution under test, with that of normal plasma
assayed at the same time, or it can be expressed in arbitrary units
whereby one unit indicates the activity of a 1/24- dilution and 12 units
that of a l/2 dilution of plasmin solution. Each unit is an increment
in reciprocal of two. Normal plasma antifibrinolytic values are 4.-8
units or l/S - l/lO titres.
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INVESTIGATIONS INTO THE FIBRINOLYTIC SYSTEM IN CERTAIN
CONGENITAL AND HEREDITARY HAEMOREHAGIC DISORDERS ;
A CRITICAL EVALUATION OF THE THEORY OF DYNAMIC HAEMOSTASIS.
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Introduction
It is now accepted that excessive fibrinolytic activity can occur
in a wide variety of physiological and pathological states and not
uncommonly in the latter this can give rise to abnormal bleeding (Tagnon,
Schulman, Whitmore and Kravitz, 1952). The effect of the fibrinolytic
mechanism on coagulation is mediated through two main channels: (a)
the digestion of certain coagulation factors, mainly factor I (fibrinogen),
factor V and factor VIII (antihaemophilic globulin) (Koller, 1961) and (b),
by defective fibrin polymerization (Alkjaersig, Fletcher and Sherry, 1962) .
In spite of such relation between fibrinolysis and some coagulation
factors and of the possible role, subsequently, of an increased fibrinolytic
activity in providing a trigger action for, or enhancing an existing
coagulation defect in haemorrhagie states (see p. 4- ), reports on the
fibrinolytic system in these cases have been infrequent.
Mole in 194-8 was the first to draw attention to the possible physio¬
logical role of fibrinolysis in preventing thrombi from being formed on
the vascular endothelium in health and suggested that atherosclerosis might
result from the failure of this defence mechanism. Copley (1954-1 1957)
postulated that, in vivo, there existed a dynamic equilibrium between two
opposing forces, the one depositing fibrin on the vascular endothelium
(the coagulation mechanism) and the other constantly removing it (the
fibrinolytic mechanism). A balanced harmony between the actions of these
two processes helps to maintain the integrity of the vascular endothelium.
According to this theory a disturbance of the balance might result in
abnormal fibrin'deposition, subsequently leading to atherosclerosis and/or
thrombus formation, or produce a haemorrhagic state. This view has
received support from other workers (Astrup, 1956; 1956 a; Jensen, 1956;
Fearnley, 1961) for it has offered an attractive and apparently accepted
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explanation for the perplexing pathogenesis of the thromboembolic
syndromes. Further support has been given to it by the findings of
a decreased fibrinolytic activity after myocardial infarction and
intermittent claudication (Nestel, i960) and after fatty meals (Tilliman,
O'Neal, Thomas and Hixon, i960).
The concept of a physiological dynamic equilibrium does, however,
not accord with the findings of other xrorkers of a lack of such
correlation between fibrinolysis and atherosclerotic heart disease (Berry,
I962) nor between fibrinolysis and lipaemia (Hougie and Ayers, I960;
Blix, 1961). Lewis, Ferguson and Schoenfeld (1961) questioned the theory
after they demonstrated that anticoagulants did not lengthen fibrinogen
survival time in dogs. Doubt was also cast on the theory from the
studies of fibrinogen turnover in haemophilia which was shown to compare
with that in normal individuals(kausen, Gruchaud, McMillan and Gitlin 9
1961). Oiwin, Oiwin and Baluda (1962) similarly questioned the validity
of the theory when they found that there was no change in the rate of
passage of an Evans blue-albumin complex through the vascular wall during
an induced fibrinolytic state in dogs.
If this theory holds true them, a change in one of the components of the
equilibrium state, for example a delayed or diminished coagulation mechanism
as in certain haemorrhagic disorders, should lead to a balancing diminution
in the other component and hence to a decrease in fibrinolytic activity. This
postulate forms the basis of the present investigations in certain haemorr¬
hagic disorders.
Materials and methods.
Thirty-seven successive patients suffering from various haemorrhagic
disorders, all in a clinically quiescent stage, were selected for study from
the regular attenders at the afternoon Out-Patient clinic for Coagulation
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Disorders. Of these thirty-seven patients, twenty-four had factor VIII
deficiency (classical haemophilia), four had factor IX deficiency (Christmas
disease), seven had von Willebrand's disease and two had hereditary
haemorrhagic telangiectasia. Six of these haemostasis deficient patients
were studied while undergoing operative procedures (five for dental
extractions and one for a minor orthopaedic operation). In all six, the
operations were done under general anaesthesia and under transufsion cover
of fresh frozen plasma and/or human antihaemophilic fraction prepared by
Blomback method. No abnormal bleeding developed during these operations.
Blood samples were taken on the morning immediately prior to the operation,
on completion of the operation and on the first day post-operatively.
Blood was taken by clean venepuncture (through a siliconed needle
hypodermic, 21 SWG) into a siliconed syringe and mixed with 3.8% sodium
citrate solution (B.P.) in the proportion of 9 parts of blood to 1 part
of citrate solution.
The fibrinolysin and/or activator activity, the antifibrinolysins,
the plasminogen and plasmin contents of the plasma were measured by above
detailed techniques. The fibrinogen was estimated by the Kjeldahl method
(Normal = 200 - 500 mg.%).
Results.
The values for the parameters measured in the quiescent phase of the
patients under investigation are shown in table IV. Table V gives the
values obtained in six of these patients over the operation phase.
Table IV shows that the 'fibrinolytic activity' and/or the 'activator
activity' as well as the fibrinogen values were within normal limits during
the quiescent phases in the patients investigated and that the antifibrino-
lytic activity was within the normal range in twenty-five cases, moderately
increased in six (Nos. 1, 9, 12, 14, 17 and 31) and moderately decreased in
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the other six cases (Nos. 21, 22, 24-, 28, 35 and 37).
Of twelve patients plasminogen assays were normal in ten, but of
these ten, three were high normal (Nos. 7, 9 and 23), one of these
three (No. 7) having in addition a high plasmin level, and one other
of these ten (No. 37) having a low normal plasminogen level. Of the
remaining two patients one showed a definite decrease in plasminogen
together with an increase in plasmin (No. 17) and the other case (No. 33)
showed an increase in plasminogen.
Out of eleven patients in whom fibrin plates were done, nine showed
normal and two (Nos. 7 and 17) high, plasmin levels. All six cases
undergoing operative procedures showed a transient increase in fibrinolytic acti¬
vity which had reverted to normal on the first post-operative day. The
antifibrinolysin(s) steadily increased in four cases (Nos. 1, 2, 3 and 4),
diminished in one (No. 5) and remained constant in the last case (No. 6).
Fibrinogen was ultimately raised in five cases and minimally changed in
one case (No. 3). In three cases (Nos. 2, 3 and 5) a rise of fibrinogen
was preceded by an initial drop in its level, concurrent with the increase
in fibrinolytic activity.
Discussion.
In previous reports the fibrinogen level in haemophilic blood has
more than once been reported as normal quantitatively as well as
qualitatively (Sj/lin, 1959). Results of our investigations in clinically
quiescent phases of various bleeding disorders confirm this finding.
Occasional results of plasminogen, plasmin and antiplasmin values outwith
the normal range obtained in these studies may possibly be, in some cases
at least, manifestations of subclinical activity of the haemorrhagic
diathesis. Marked increase in antifibrinolytic activity has been found
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sporadically even in normal people (Biezenski, i960). These findings
make speculation very hazardous as to whether an exaggerated fibrinolytic
activity is the cause or the result of a spontaneous crisis in a bleeder.
The response of the fibrinolytic mechanism to operative procedures
found here conforms with what has been previously reported with operative
procedures viz transient rise of fibrinolytic activity (Macfarlane,
1937; Sforza and Pozzi, i960 a) with sometimes an opposing increase in
antifibrinolysins (Sandberg, Tsitouris and Bellet, i960). An ultimate
rise of fibrinogen is expected as a result of the operative stimulus. It
seems therefore that the fibrinolytic system is normal in these reported
diseases in most of which there is known to be a delay in the haemostatic
mechanism, and that its activation during and following operation followed
a normal sequence.
It has been mentioned earlier that the theory of dynamic physiological
equilibrium governing coagulation and fibrinolysis - a theory which has no
substantial proof - has been criticised in different respects;(a),
anticoagulants do not lengthen fibrinogen survival times (Lewis, Ferguson
and Schoenfeld, 1961); (b), fibrinogen turnover in haemophilia is the same
as that in normal individuals (Rausen, Cruchaud, McMillan and Gitlin, 1961)
and (c), there is no change in the rate of passage in fibrinolytic states
of an Evans blue-albumin complex through the vascular endothelial wall nor
in its rate of excretion from the body (Oiwin, Oiwin and Baluda, 1962).
Further, if deposited fibrin is normally under continuous removal one
would expect to find an effective level of the active fibrinolytic enzyme
(plasmin) in the circulation of normal individuals in order to carry out
this function. This is known not to be the case and no free plasmin
appears in circulating plasma (McWicol, 1962).
Evidence therefore suggests that this over simplification of the
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coagulation-fibrinolytie mechanism is not true and that its role in the
aetiology of atherosclerosis and of thromboembolic disease is not clear.
It could be that the fibrinolytic mechanism enters into action in 'alarm'
conditions; the role of physical and mental stress in enhancing the
fibrinolytic activity is well established. This is substantiated by
a recent report in which a technique was developed for teeth extractions
in haemophilics that has eliminated the need for plasma or blood transfusion,
and shortened considerably, or made unnecessary, any hospitalization (Lucas,
Carroll, Finklemann and Tocantins, 1962). The method reported took
advantage of hypnotic suggestion to avoid or alleviate all excessive
physical and psychological stress before, during and after the operative
procedure,,
Summary
Investigation of the fibrinolytic system in a total of assorted
thirty-seven cases of congenital and hereditary disorders of the
haemostatic mechanism was carried out when these patients were clinically
quiescent and when six of them underwent operative procedures.
On the basis of the parameters investigated,the fibrinolytic system
was found to be normal in these individuals and to react normally to
operative trauma.
It was concluded that if the theory of a physiological dynamic
equilibrium between coagulation and fibrinolysis holds true, a delay
in the initial process such as occurs in most of the patients investigated
should be balanced by a decrease in the second process. Our results
show no evidence that such a disturbance occurs and it was suggested
that the fibrinolytic mechanism may enter into action in 'alarm'
conditions.
TableIV
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In 1954-, Gibbon after many years of experimental work achieved
the first successful total body perfusion in a human body using a
form of cardiopulmonary bypass. A prime aim of all workers in
this field since has been to produce safe and adequate anticoagulation
of the blood during such a procedure and to reverse it swiftly and
safely at the end of the operation. Furthermore it was necessary
that there should be none, or at the most, a minimal and insignificant
alteration in both the cellular and humoral elements of the blood due to
this procedure and although satisfactory results have been achieved
we are still far from perfection. Reports of haematological changes
during extracorporeal circulation have varied particularly in the
coagulation mechanism.
There has been no general agreement on the occurrence of
bleeding tendencies, and, where these have been reported, there has
been a wide diversity of opinion as to their cause. Many theories
have been advanced to explain the aetiology of excessive bleeding
during extracorporeal circulation in open-heart surgery and among
these have been pyrogens, type of apparatus, duration and rate of
perfusion (Brown and Smith, 1958), inadequately cleaned and sterilized
equipment, incompatible blood or inadequate haemoatasis (DeWall, Long,
Gemmill and Lillehei, 1959), active trauma (Osborn, MacKenzie, Shaw,
Perkins, Hurt and Gerbode, 1955), massive blood transfusion (Matzke,
Jensen and Rygg, 1961), heparin rebound phenomona (Holemans, Vermylen
and Verstraete, i960) de novo development of circulating anticoagulants
(von Kaulla and Swan, 1958), activation of the thromboplastin mechanism
with consumption of essential coagulation factors (Ollendorff, Storm,
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Rygg and Arnfred, 1961), secondary hypocoagulation after heparin
neutralization (Matzke, Jensen and Rygg, 1961), type of cardiac
lesion (Gans, Lillehei and Krivit, I96I) and other unknown causes
(Cooley, Belmonte, DeBakey and Latson, 1957).
Thrombocytopenia, constantly follows the procedure and it is
believed that it can cause a serious bleeding disorder (Perkins,
Osborn, Hurt and Gerbode, 1956). Excessive fibrinolysis, however,
has been the next most commonly reported disturbance and has sometimes
given rise to serious bleeding (Perkins, Osborn and Gerbode, 1958).
Activation of the fibrinolytic system has since been shown to be
conditioned by an in vivo factor, and this has sometimes apparently
been dependent on the rate and duration of perfusion and on the pH
changes occurring (von Kaulla and Swan, 1958). The time of onset
of maximum fibrinolytic activity during extracorporeal circulation
has born no relation to any specific cause. Reports on alterations
of components of the fibrinolytic system due to bypass, namely the
fibrinolysins and fibrinogen have varied and little heed has been
paid to the antifibrinolytic and the other inhibitor systems.
It is the object of this study to determine and discuss changes
in the fibrinolytic system observed in eighteen patients with cardiac
disease who were submitted to open-heart surgery and cardiopulmonary
bypass.
Materials and Methods
Eighteen patients undergoing cardiopulmonary bypass and open-heart
surgery for various cardiac diseases in the Royal Infirmary of Edinburgh
formed the subject of this study. Table VI lists the relevant
particulars of each patient. The patients were selected only on their
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anticipated availability for obtaining adequate blood specimens at
fixed times throughout their operative history.
Extracorporeal circulation using a Melrose N.E.P. rotating disc
pump oxygenator was used with hypothermia down to a temperature
averaging 30-31°C. The machine was primed using fresh heparinized
blood (30 mg. heparin in 15 ml. sterile normal saline to which was
added 400 ml. of fresh blood) collected on the morning of the operation
and stored at 4° C,, until needed. Blood donors had previously been
screened routinely for abnormal antibodies, crossmatched with the
patient and intermatched with one another.
The patients were heparinized immediately prior to cardiac
cannulation using 3 mg. of heparin per kilogram of body weight and
reversing it post-operatively with hexadimethrine bromide well diluted
in sterile 5% dextrose given slowly in not less than ten minutes to
avoid circulatory disturbance (MacKenzie, Wade, Davies and Zellos 1961).
The neutralization of heparin x^as deemed complete when the thrombin
time returned to pre-heparinization level and was not further shortened
by the prior addition of toluidine blue to the test plasma. Additional
doses of hexadimethrine bromide were given if required until this was
achieved. Heparinization during bypass was considered adequate when
the thrombin time was not less than 60 seconds (control 10-12") and the
clotting time (Lee and White) not less than 60 minutes0 During
anticoagulation 10 ml. blood specimens were obtained as required from
the circuit but at other times blood was drawn into heparin in a
concentration of 5 units/ml. of blood. Specimens were taken (1) before
anaesthesia, (2) a few minutes before bypass, (3) a few minutes after
commencing bypass, (4) at the end of bypass, (5) a fex* minutes after
reversal of the anticoagulation and (6) 30 minutes later.
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Fibrinolytic activity and/or activator activity was measured
by the euglobulin lysis time, modified for heparinized blood
vide supra (p.A7 ).
Antifibrinolysins and caseinolytic plasminogen assays were
done according to above described methods (p. AS,4-9) Fibrinogen was
estimated by the Kjeldahl technique, normal values being 200-500 mg,%
Results
Table VII shows the results obtained in these tests.
Fibrinolysis: Excessive fibrinolysis was found in all of the
cases at some time during the procedure. On 9 of these occasions the
maximum fibrinolytic activity was found during bypass, on 7 occasions
after hexadimethrine bromide reversal of the anticoagulation and on
2 occasions during anaesthesia but immediately prior to the onset of
bypass. Enhanced fibrinolytic activity was transient and had abated
30 minutes at the most, after reversal of the coagulation mechanism.
In spite of the demonstration of an abnormal fibrinolytic activity in
all the cases, only one transient clinically significant fibrinolysis
was met with (case No. 19) causing an uncontrolled haemorrhage for
less than thirty minutes and it abated spontaneously. Apart from
case No. 5 who died from cardiac arrest, all other cases recovered
from the operative procedure and had no serious clinical disturbances
of the haemostatic mechanism.
Fibrinogen: In all the cases and usually concomitant with a
rise in fibrinolytic activity, a variable decrease in fibrinogen level
was noted.
Antifibrinolysins: In 8 cases (Nos. 1,8,9,11,12,13,16 and 17)
antifibrinolysins decreased during the operation, returned to normal and
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sometimes even showed a slight increase above normal after reversal
of anticoagulation post-operatively. A steady increase was found in
4- cases (Nos. 2,7,10 and 18) and a steady decrease in another 4-
(Nos. 5,6,14- and 15). One case (No. 3) showed an increase in
antifibrinolysins before returning to normal levels and there was
virtually no change in one case (No.4).
Plasminogen: Of 7 cases in which plasminogen levels were
determined 5 showed a decrease which had reverted spontaneously to
pre-operative levels by the time the final sampling was done 30 minutes
after the administration of the hexadimethrine bromide though one case
showed a final rise in plasminogen (No. 14-) and the other a final
decrease in it (No. 13).
Discussion
From this study of the fibrinolytic system during extracorporeal
circulation in open-heart surgery, it would seem that excessive
fibrinolysis is inevitable at some time(s) during the procedure,
causing, however, no serious consequences when those described methods
are used. It is suggested that mechanical trauma might play a part
in this increased fibrinolysis, either per se. or through activating
thromboplastin, since in most cases the maximum rise in activity has
coincided with the end of the bypass. The occurrence of the same
phenomenon in 7 cases following heparin neutralization might be explained
by the removal of an inhibitory effect exerted by heparin on the fibrinolytic
system though the role of heparin in fibrinolysis is not clear (von KauIIa
and McDonald, 195&J Douglas, I962).
The role of the antifibrinolysins is less certain and. has been
much less investigated. After some operations an increase of inhibitors
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has been reported (Sandberg, Tsitouris and Bellet, i960) whilst in
some experimentally induced fibrinolytic states there has been an
increase, followed by a decrease, in the antifibrinolysin titre
(von Kaulla, 1958). The role of fibrinolytic inhibitors is at
present not really known partly because of the complicated technical
procedures employed in cardiopulmonary bypass and to the many drugs
used during it.
Decreases in plasminogen and fibrinogen levels during cardio¬
pulmonary bypass found in the present study accords with reports on
similar decreases associated with a fibrinolytic state (Sawyer, et al.,
i960j Nilsson and Olow, 1962).
Summary
The changes in the fibrinolytic system observed in eighteen
patients with cardiac disease undergoing open-heart surgery on
cardiopulmonary bypass with hypothermia was studied.
This investigation revealed that excessive fibrinolysis is
inevitable at some time during the procedure, but need not, however,
cause any serious consequences as shorn in the patients studied.
Plasminogen and fibrinogen diminution was noted, while changes in the
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A COMPARISON OF HAPTOGLOBIN PHENOTXPES IN HAEMOPHILICS
AND NORMAL PERSONS IN SCOTLAND.
Fig. 5 * a. Haptoglobin type 2-1, b. type 0-0, c.




When normal plasma is subjected to electrophoretic analysis in
free solution or in a supporting medium such as filter paper or cellulose
acetate, six components can usually be identified; these are albumin,
the alpha 1, alpha 2, beta and gamma globulins and fibrinogen. Quantit¬
ative variations in such components have been related to various disease
states. When, however, normal plasma or serum was run electrophoretically
on starch-gel by Smithies in 1955 he obtained nine to twelve fractions
and from these he described three distinct genetically determined types
of plasma protein patterns. The differentiation into these three types
was based on variations in a protein fraction known as the 'haptoglobins'.
Haptoglobins are glycoproteins which have the specific function of binding
free haemoglobin liberated intravascularly and facilitating its elimination
via the reticuloendothelial system (Eastham, 1961). Haptoglobins form
part of the alpha 2 globulin fraction in conventional electrophoresis
(Harris, Robson and Siniscaleo, 1959)j the haptoglobin-haemoglobin complex
migrates with the beta 1 fraction, any free haemoglobin moving between
the beta and gamma portions (Miale, 1962). The three main haptoglobin
phenotypes are 1-1, 2-1, and 2-2. These phenotypes are determined by
12
a pair of autosomal allelic genes, Hp and Hp (Smithies and Walker, 1955j
Galatius - Jensen, 1957). Other inherited variants of the three common
types of haptoglobins have recently been reported (Smithies and Connell,
1959).
Both ahaptoglobinaemia which may be either familial or arise
1 2
spontaneously by mutation or by suppression of the Hp or Hp genes, and
decreased concentration of serum haptoglobins may be found in disease
states such as haemolytic diseases (Wosslin and Nyman, 1958)= Racial
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differences in haptoglobin types have been reported and ascribed to
genetic factors such as G.-6-P.D. deficiency and to environmental
factors such as malaria and liver disease (Mehta and Jensen, i960).
Quantitative changes in haptoglobins have been described in a variety
of disease conditions in which there is inflammation or destruction
of tissues as in acute pyogenic infection, rheumatic fever and malignancy
(Jayle and Boussier, 1955), and in hepatobiliary disease (Owen, Mackay
and Got, 1959 )<> Phenotypic changes in the concentration of haptoglobins
might, it is thought, be of some value in determining their physiological
and genetic significance (Allison, 1958). No clear cut relationship
has yet been found between haptoglobin types, transferrin types and
specific clinical disorders; perhaps, however, as Allison (1958) points
out, due to the relatively small number of individuals so far tested it
would only have shown up had the correlation been high. Reports on
such associations have been controversial(Sutton, Neel, Livingstone,
Binson, Kunstadter and Trombley, 1959; Mehta and Jensen, I96O; Bennett,
1961; Bennett, Auricht, Gray, Kirk and Lai, I96I) and it has been
recommended that work on this matter should be extended (Harris, Robson
and Siniscaleo, 1959).
It was considered desirable, therefore,to determine the haptoglobin
phenotypes in patients with factor VIII deficiency and other hereditary
haemostatic disorders in an endeavour to find yet another genetic link
or tracer for them. There is already an infrequently reported occurrence
of factor VIII deficiency with other genetically determined deficiencies
of factors V, VII, IX and XI, with vascular and platelet abnormalities, and
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with a freezing/serum factor (see p. 3 )• Of prime importance in this
respect is the reported use of the genetic relation between factor VIII
deficiency, red-green colour blindness, one form of muscular dystrophy,
Xg blood groups and G.-6-P.D. deficiency in the study of the X chromosome
cartography (Race, i960; Tarleton, Race and Sanger, 1962)0 Of added
interest is the discovery that factor VIII, a deficiency of which
constitutes the basic defect in classical haemophilia, migrates in the
alpha 2 and alpha 1 serum fractions in continuous flow electrophoresis
(Lewis and Merchant, 1959) and it is known that the haptoglobins also
migrate in the alpha 2 component (Harris, Robson and Siniscalco, 1959)*
The pattern of distribution of several haptoglobin types within
those human populations so far studied (Harris, Robson and Siniscalco,
1959; Arends and Rodriguez, I960; Barnicot, I96I) may be part of a true
polymorphism like that of blood groups affecting all human populations or
be characteristic of certain areas of the world as are the haemoglobin
variants. It has been thought likely that such polymorphisms may be
maintained by a balance of selecting forces acting upon the different
genotypes (Allison, 1958). The idea that people with certain blood
groups are more susceptible to various diseases (Roberts, 1957) has not
been universally accepted (Awny and Kamel, 1959; Wiener, 1962). It
has been reported that the distribution of blood groups in haemophilics
follows the normal pattern (ikkala, I960). The present study whose
purpose is to investigate the genetically determined serum haptoglobin
types in certain hereditary haemorrhagic disease conditions, might it
seemed, help to elucidate these problems.
Material
Blood specimens were collected from 24- patients with factor VIII
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deficiency (classical haemophilia), 5 with factor IX deficiency
(Christmas disease), 7 with von Willebrand's disease and 2 with
hereditary haemorrhagic telangiectasia all attending the Out-Patients
clinic for Coagulation Disorders, The Royal Infirmary, Edinburgh.
For normal local controls, blood was obtained from 100 consecutive
pregnant healthy females of Scottish extraction referred to the
Blood Transfusion Service, The Royal Infirmary, Edinburgh, for routine
antenatal screening. These controls were considered to be satisfactory
since the incidence of haptoglobin types does not vary with sex
(Smithies, 1955) and, being congenitally determined, does not vary with
the physiological process of pregnancy.
Methods
Haptoglobin typing has been done by starch-gel electrophoresis in
a discontinuous system according to methods previously described (Kamel,
1959/1961).
✓
The reagents used in this technique are :
1. Hydrolysed potato starch. Connaught Medical Research Laboratories,
Toronto, Canada, batch No. 152. This was used in a concentration
of 11.4- G. per 100 ml. gel mixing buffer.
2. Gel mixing buffer. This citrate buffer (0.076 M Tris, 0.005 M citric
acid, pH 8.8).
Tris - (Hydroxymethyl) aminomethane 9*19 G./L.
Citric acid 1.00 G./L.
3. Bridge solution buffer (0.3 M boric acid, 0.05 M sodium hydroxide
pH 8.4-)
Boric acid 18.5 G.
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Sodium hydroxide (N/l) 50 ml.
Distilled water up to 1000 ml.
A. Stains
a. Benzidine stain. A mixture of 100 ml. distilled water,
0.5 ml. glacial acetic acid, 0.2 G. benzidine is warmed
to dissolve the benzidine then 0.2 ml. of a 30% W./V.
solution of hydrogen peroxide '100 vol.• are added. The
benzidine stain should be prepared immediately before use.
b. Naphthalene black stain. Saturated solution.
Naphthalene black B 10 2.0 G.
Methanol-acetie acid solution 200 ml.
c. Methanol-acetic acid solution
Methanol 50 vol.
Glacial acetic acid 10 vol.
Distilled water 50 vol.
After saturating the haptoglobins with added haemoglobin the plasma
or serum was subjected to electrophoresis in a starch-gel 25 x 15 x 0.6
cm. in dimensions. A direct potential of 120 volts, corresponding to a
current of 9-11 milliamperes was applied for approximately 20 hours
(overnight).
After completion of the run and slicing the gel through its thickness
into two, one slab was treated with benzidine which clearly delineated
the different haptoglobin types and the second slab was stained with
naphthalene black for further confirmation and study.
Figure 5 illustrates the four types of haptoglobins shoxvn as haptoglobin-
haemoglobin complexes that have been found in this study. Type 0-0
individuals are those who show no haemoglobin-binding protein, but show
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free haemoglobin in the starch-gel.
Because of the belief that there are two controlling allelic genes
for each haptoglobin type and in order to compare the results statistically
with previously reported studies (Mehta and Jensen, I960; Bennett, I96I),
individuals with ahaptoglobinaemia (type 0-0) were excluded in calculating
the gene frequencies. Expected values for various haptoglobin phenotypes
have therefore been calculated on the basis of the Hardy-Weinberg equation
2 2 1
(type l-l=p , type 2r-l = 2pq and type 2-2 = q where p=Hp gene frequency
2
and q = Hp gene frequency).
Results
Table VIII shows the haptoglobin types and estimated gene frequencies
found in haemophilia, in some other haemostatic disorders and in one hundred
local normal controls in this study. There were four phenotypic groups in
the haemophilies and the controls:1-1, 2-1, 2-2 and 0-0. Estimated gene
frequencies cannot be deduced from the haptoglobin types in the cases of
factor IX deficiency, von Willebrand's disease and hereditary haemorrhagic
telangiectasia reported in this study because of the small numbers of
patients involved.
Discussion
Ahaptoglobinaemia which is a physiological state in newborn infants
(Miale, 19&2) was also found in 3 per cent of our normal adult controls, an
incidence similar to that in England, 2.7 per cent (Allison, Blumberg and
ap Rees, 1958) and in neighbouring European populations (Harris, Robson and
Siniscalco, 1959; Arends and Rodriguez, I960; Barnicot, 1961; Miale, 1962).
The distribution of haptoglobin types in various populations is shown in
table IX for purpose of comparison. The distribution of the phenotypes
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1-1, 2-1 and 2-2 and the estimated gene frequencies Hp and Hp
match those found in England and both are in accord with the
average known gene frequency of Hp"'" among Oaucasoids, 0.34- -
0.4-6 (Arends and Rodriguez, i960). Although there were apparently more
Hp types 1-1 in the haemophilics (25%) than in the controls (10%)
o
the difference is not statistically significant. An x test for the
distribution of the three haptoglobin types in these haemophilics and
in the local controls gives a value of 2.01 for two degrees of freedom.
Accordingly is more than 0.30 and this indicates that a real
difference in the haptoglobin types of the two groups is very improbable
(Smithies, 1955).
In-our study, starch-gel electrophoresis of haemophilic blood has
not shown any abnormal or characteristic zones which can be related to
the a^ globulin previously described (Bernfeld, Stefanini, Berkowitz
and Hennessey, 1953). Factor VIII which is known to be present in
plasma in very small amounts (Wagner, Brinkhous and Penick, 1959) has
never been isolated in a pure form. It appears that the defect in factor
VIII activity in classical haemophilia is not of a nature which would
allow of its detection by the electrophoretic methods described. Although
the number of patients with diseases other than haemophilia reported
in this study are too small for statistical analysis of their haptoglobin
types, their electrophoretic patterns showed no obvious abnormalities.
More patients with these conditions will have to be investigated before
any firm conclusions can be dram.
In many diseases the distribution of haptoglobin types and/or
blood groups has been found to accord with those in normal individuals
(Craig and Wang, 1955; Allison and Blumberg, 1958; Awny and Kamel, 1959;
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Bennett, 1961; Bennett, Auricht, Gray, Kirk and Lai, I96I; Gunson
and Smithies, 1962), and Ikkala (i960) confirmed the normality of
blood group distribution in haemophilics. In the present investigation
no statistically significant difference was found between the haptoglobin
phenotypes of haemophilics and of normal individuals.
Summary
Haptoglobin phenotyping by starch-gel electrophoresis Was determined
on 100 normal individuals in Scotland and on 38 patients with hereditary
haemorrhagic diseases.
Haptoglobin type distribution in the controls accords with that of
neighbouring populations.




Haptoglobin Phenotypes and Gene Frequencies in
Scotland and in Certain Hereditary Haemorrhagic Disease States
Population
Haptoglobin types Estimated gene
Values Total 1-1 2-1 2-2 0-0 frequencies
Hp Hp2
Normals Observed 100 10 49 38 3 0.36




Observed 24 6 9 8 1 0.4-6
Expected 4.87 11.42 6.71
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PLASMA THROMBOPLASTIN GENERATION BLOCKING
ANTICOAGULANT IN HAEMOPHILIA
CLINICO-PATHOLOGICAL STUDY OF A REFRACTORY CASE
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Introduction
Since first demonstrated by Weil in 1906, circulating anticoagulants
have been reported in cases of classical haemophilia, that is, haemophilia
due to a deficiency of antihaemophilic factor, and closely allied blood
coagulation disorders by many workers (Munro, 194-6; Graddock and Lawrence,
194-7; Singer, Mond, Hyman and Levy, 1950; Lewis, Ferguson and Arends,
1956; Verstraete and Vandenbroucke, 1956; Harmon, Zipursky and Lahey, 1957;
Biggs and Bidwell, 1959; Sise, Gauthier, Desforges and Buker, 1962).
Such circulating anticoagulants have also been reported in the blood of
patients who seemed otherwise to be normal or who had other diseases, notably
systemic lupus erythematosus (Margolius, Jackson and Ratnoff, 1961). The
acquired circulating anticoagulant described in patients with classical
haemophilia has appeared always to inhibit the formation of thromboplastin
activity in the early stages of coagulation. This inhibition was accomplished
by either inactivating or destroying factor VIII (antihaemophilic factor)
(Stefanini and Dameshek, 1955; Biggs and Bidwell, 1959) i.e. the anticoagulant
was directed specifically against factor VIII, and this action was illustrated
by recent reports (Hall, 1961; Breckenridge and Ratnoff, 1962; Sise,
Gauthier, Desforges and Buker, I962). A method for the measurement of these
circulating anticoagulants has been based on the speed with which the anti¬
coagulant neutralizes factor VTII (Biggs and Bidwell, 1959).
This part of the thesis presents a clinical and laboratory study of a
patient with classical haemophilia who developed an unusual form of circulating
anticoagulant. The anticoagulant in this case was directed against the
production of plasma thromboplastin activity, thus blocking further reaction in
the coagulation chain. Factor VIII wqs not directly antagonized and could in
fact be maintained at high haemostatic level for a period without exhibiting a
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a corrective effect on the coagulation mechanism.
Methods
Blood counts were carried out by standard methods (Dacie, 1956). The
Ivy bleeding time, Hess tourniquet test, Lee and White clotting time, clotting
time in silicone! tubes, plasma recalcification time, thrombin time, one-
stage prothrombin time, prothrombin consumption index, factor VIII assay,
thromboplastin generation test, demonstration of circulating anticoagulant
by its effect on normal plasma and effects of the anticoagulant on brain
thromboplastin were all performed according to the methods of Biggs and
Macfarlane (1957). Fibrinogen estimation was done by the Kjeldahl method
and euglobulin lysis time by the method described above (p. 17). Plasma
proteins were fractionated by precipitation with various concentrations of
ammonium sulphate. Each fraction was reconstituted to its original plasma
volume with veronal buffer pH 7.5. The percentage prolongation in recal¬
cification time of normal plasma produced by the admixture of 30% reconstituted
fraction was arbitrarily taken as relative activity of the anticoagulant in
the individual fractions. Precipitin tests on cellulose acetate were
performed by an Ouchterlony technique and Grabar immunoelectrophoresis.
Antihaemophilic Fraction for transfusion was manufactured and supplied by
the Edinburgh and South East Scotland Blood Transfusion Service. It was
prepared by ethanol precipitation from fresh plasma and further purified in
ethanol glycine by Blomback's method. Platelet-poor citrated plasma
obtained from adding nine volumes of blood obtained by clean venepuncture
to one volume 3.8$ sodium citrate (B.P.) has been used throughout these tests.
Clinical Study
The patient, a 4-0-year old male, was a known haemophilic with a positive
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family history. He had suffered from recurrent haematuria since
infancy, the attacks occurring primarily twice each ■winter until more
recent years when he had only one episode annually. During many
episodes of haematuria the patient had had attacks of renal colic
occurring on either side. He had also suffered easy bruising all
his life but only had two haemarthroses, both traumatic, resulting in
residual damage in the joints, viz. right knee and left ankle. He
was able to play football at school and to work as a labourer until
5 years prior to the present investigation. For 10 years before the
last admission, haematuria was usually treated by bed rest at home and
cleared up rapidly. During an attack of haematuria in 194-7 he was admitted
to a London Hospital and had an uneventful cystoscopy and retrograde
pyelography with minimal blood transfusion cover. On this occasion
blood was seen coming from the left ureter and there was mild bilateral
hydronephrosis and hydroureter but no evidence of any other local lesion.
During the 10 years before the present admission he had largely been
treated in hospital for his episodes of haematuria, being transfused with
fresh plasma or blood, and controlled rapidly and effectively and without
assay of factor VIII content by small amounts given over a short time.
He had had no other illnesses of note.
The present episode of haematuria began in February, 1961, settling
after one month but recurring five weeks later and resulting in the
patient's admission to hospital. He was treated with plasma and blood
transfusions without effect and was then transferred to a specialist
hospital unit on May 2nd, 1961, where the diagnosis of haemophilia was
confirmed; intravenous pyelography done twice in a month shoved mild
bilateral hydronephrosis. Coliform organisms were cultured repeatedly
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from the patient's urine and he was treated with chemotherapy and
antibiotics under bacteriological control until finally B. Proteus
was isolated. This organism was sensitive only to 'Neomycin' but he
was not given this drug. Repeated investigations for Mycobacterium
tuberculosis in the urine were negative. The urinary function tests
were within normal limits. The patient had osteoarthritis changes
consistent with old haemarthrosis in his right knee joint and left ankle.
He was repeatedly transfused with fresh blood and plasma without any
significant improvement in his clotting time or in his haematuria and
it was subsequently found that he had a circulating anticoagulant in
his blood and was then transferred to the Royal Infirmary of Edinburgh
on July 6th, 1961.
Laboratory investigations here confirmed the diagnosis of
haemophilia with a circulating anticoagulant which acted by blocking
thromboplastin generation, and not specifically destroying factor VIII.
Tomography of the kidneys yielded no further information. Repeated
early morning urines and mid-stream urines for bacteriological study
were obtained. Intravenous "Pyrexal" followed by colony counts of
mid-stream urines at hourly intervals was also done and all these tests
proved to be negative. The patient was then given one "unit" human
Antihaemophilic Fraction reconstituted in 200 ml. water intravenously
every two hours, a unit being the amount prepared from 1,600 ml. fresh
A.C.D. plasma. This was repeated six hourly and each Fraction followed
immediately by 4-00 ml. fresh frozen plasma given over the next four hours.
He thus received the equivalent of 8,000 ml. fresh plasma per day. By this
means the factor VIII level of his blood could be raised to normal but the
circulating anticoagulant still largely blocked utilization of that factor
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so that the clotting time remained prolonged and the haematuria, although
diminished (urinary haemoglobin reduced from 1.16 G.% to less than 0.1 &.%)
still continued® It was therefore decided to stop transfusion with
Antihaemophilic Fraction and merely maintain the haemoglobin level by
transfusions of washed erythrocytes as needed in the hope that by not
giving any antihaemophilic factor intravenously the stimulus for the
circulating anticoagulant would be removed and its level therefore
spontaneously fall. One week later, however, there was no change in
anticoagulant titre. The patient was then given oral 'Prednisone' 60 mg.
a day with potassium supplement in an endeavour to block the action of
the anticoagulant. Unfortunately there was no clinical or laboratory
evidence of this happening. Two days later the patient complained of
pain in the left hip and was found to have a positive left psoas sign
with limitation of movement of the hip joint and hypoaesthesia of the
segments supplied by LL - L4, and weakness of his left quadriceps muscle.
It was concluded that he had had a retroperitoneal haematoma into the left
psoas sheath and, straight X-ray of the abdomen showed loss of the left
psoas shadow. In view of this new bleeding it was decided to give him
large doses of porcine Antihaemophilic Fraction in an attempt to overwhelm
the blocking anticoagulant. He was given an initial dose the equivalent
to 8,000 ml. of fresh plasma to be repeated eight hourly. The laboratory
tests, however, whilst showing blood factor VIII levels in excess of 100
per cent following transfusions, showed that the blocking action of the
anticoagulant was unaffected and the haematoma rapidly spread retroperitoneal^
on the left side and extended into the pelvis. The patient required frequent
heavy sedation to control the severe abdominal pain and rapidly became
oliguric, the urine still being heavily blood stained. He deteriorated
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progressively over the next 24- hours and there was clinical evidence of
continued extension of the retroperitoneal haematoma which a day later
ruptured into his pelvis and resulted in his death.
Post-Mbrtem Examination
At necropsy no lesion in his renal tract was found to account
for the haematuria. The findings of bilateral hydronephrosis and
hydroureter were confirmed, the latter extending on the right side
over the whole length of the ureter and on the left to within one
inch of the bladder. Blood was seen only in the right calyceal
system though neither kidney showed any gross cause for bleeding. The
prostate was normal. There was no evidence of gross infection in the
tract. There was a large retroperitoneal haematoma on the left side
extending from the psoas sheath upwards into the left hypochondrium
then down the lateral wall of the left flank to the pelvis into which
it had ruptured. There was no evidence of bleeding elsewhere and the
bowel was normal. The lungs showed terminal basal hypostatic pneumonia.
The coronary vessels showed fairly marked atheroma. The joints, apart
from arthritis in the right knee and left ankle were normal.
On microscopy both kidneys showed moderately sever patchy arterio¬
sclerotic damage with obliteration of glomeruli, scarring and tubular
dilatation. There were scattered haemorrhages throughout the right kidney,
both perivascular and intraglomerular. There was no structural abnormality
present in the renal tissue to explain the repeated renal haemorrhages.
Sections of pelves and ureters revealed no structural abnormality. The
myocardium showed no evidence of recent or old infarction. The coronary
tree showed a moderate degree of atheromatous damage and there was macroscopic
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evidence of severe damage in the interventricular branch of the left
coronary artery. There had been a recent haemorrhage into an atheromatous
plaque in this area producing a severe degree of stenosis, but not
complete obstruction. There was no thrombosis associated with this
haemorrhage. Sections of the lungs showed extensive congestion and
oedema, particularly in the lower lobes. Liver, spleen, prostate thyroid
and adrenals revealed no abnormality.
Laboratory findings
I. General Investigations
On admission, the patient's haemoglobin was 11.5 G.%, P.C.V. 35%,
M.C.H.G. 32%, leucocyte count 2,8Q0/cu.mm. with a differential count of
neutrophils 60%, lymphocytes 35%, monocytes 4% and eosinophils 1%.
The E.S.R. was 45 mm. in the first hour (Westergren). The urine contained
I.16 G.% Hb. Serum proteins were 8.5 G.% with electrophoretic fractions
of serum albumin 3.6 G.%, alpha 1 globulin 0.2 G.%, alpha 2 globulin 1.0 G.%,
beta globulin 1.1 G.% and gamma globulin 2.6 G.% Serum calcium was 10.7
mg.%, inorganic phosphate 2.4 mg.% and alkaline phosphatase 8 K.A. units.
Blood urea nitrogen was 15 mg.%, serum creatinine 1.05 mg.% and serum uric
acid 6.5 mg.% (normal = 1-4- mg.%). Urine creatinine was 22 mg.% and the
creatinine clearance was 112 ml./minute (normal = 90-120 ml./min.). The
urinary calcium output was 208 mg./24 hours on standard ward diet.
II. Serological Examination
The patient's blood group was A and the probable Rh genotype cDE/cde.
The direct Coombs' test was negative and no abnormal antibodies were detected
over a temperature range of 4°C. to 37°C. No platelet agglutinins were
found in the blood.
III. Clotting Studies
The following values were obtained - Platelet count 250,000/cu.mm.,
Figure 6. Thromboplastin generation test with clotting times of plasma
substrates in seconds showing 1. Normal reaction, 2. Defective reaction
of patient's plasma, 3. Normal reaction of patient's serum, L. Normal
reaction of patient's platelets, 5. Defective thromboplastin generation
with patient's plasma and patient's serum, 6. Defective reaction
with 20% patient's plasma in normal plasma, 7. Normal reaction using
the patient's plasma as a fibrinogen substrate. (Clear figures refer to
normal blood components and black ones to those of the patient).
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bleeding time 2 minutes (normal (N) = 2g to 7 minutes), Hess test
negative, Lee and White clotting time 56 minutes (N = 5-10 minutes),
clotting time in siliconed glass more than two hours (N = 18-25
minutes) and plasma recaleification time between 600 and 1,300
seconds (N = 90-250 seconds). The thrombin time was 13 seconds
(control 14 seconds), prothrombin time 14 seconds (control 13 seconds)
the prothrombin consumption index 100$ (N = 20$ or less). The
plasma fibrinogen \ms 330 mg.$ (N = 200-5CD0 mg$) and the euglobulin
lysis time 238 minutes (N = 120-330 minutes). #ssay level of factor
VIII in the patient's blood was 18 per cent (N = 60-160 per cent) and
assays of factors V, VII and IX were normal. The thromboplastin
generation test (Fig. 6) showed that whenever the patient's plasma
was used in the system the clotting time was prolonged and that four parts
of normal plasma mixed with one part of the patient's plasma did not
restore the clotting time of the fibrinogen substrate plasma to normal.
With a normal thromboplastin generation mixture, using the patient's
plasma as a fibrinogen substrate, normal clotting time was obtained.
Both serum and platelets of the patient reacted normally in the thrombo¬
plastin generation mixture.
IV. Investigations of Circulating Anticoagulant :-
1. Demonstration of the presence of an anticoagulant by its
non-specific inhibitory effect on normal blood and plasma.
(a) An equal volume of the patient's native plasma (obtained
by cold separation without added anticoagulant) added to
normal blood in silicone-coated glass tubes prolonged the
clotting time of the latter from 21 minutes to 150 minutes.
(b) Increasing concentration of the patient's plasma in
normal plasma caused progressive marked prolongation
of the recalcification time of the latter without
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incubation (Table X). The inhibitor was hardly-
demonstrable when either the normal plasma used in the
test or the patient's plasma had been repeatedly frozen
and thawed.
Test for heparinoid effect. The patient's plasma thrombin
time was not shortened by toluidine blue.
Effect on acetone dried human brain thromboplastin.
The one-stage prothrombin time test was carried out on a
normal plasma sample, on the patient's plasma and on a
mixture of both plasmas in equal parts. The clotting
time of the mixture was not significantly longer than
that of the normal plasma.
Eight mixtures of 0.1 ml. of patient's plasma and 0.1 ml.
of brain thromboplastin suspension were prepared and placed
in a water bath at 37°C. At five minutes intervals, one of
the mixtures was recaleified with 0.1 ml. M/40 calcium
chloride and the reealcification time recorded. The
test was repeated using normal plasma. No significant
lengthening of the recalcification times following incubation
of the patient's plasma over the normal plasma was found.
Test for factor VIII destruction.
Factor ¥111 content of normal plasma was estimated before
and after incubation at 37°C. for 30 minutes with an equal
volume of the patient's plasma. There was no significant
change due to incubation.
Characterization of the Inhibitory Agent
Serum inhibitory activity.
The patient's serum showed no antagonistic activity to the
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coagulation process in the thromboplastin generation test.
Also 30 per cent of barium sulphate adsorbed patient's
serum in normal plasma did not alter the reealcification
time of the latter compared to the control.
2. Storage and thermal stability.
The patient's plasma stored at -20°C. preserved its
anticoagulant activity for more than 6 weeks. Repeated
freezing and thawing of the plasma, however, had a marked
deleterious effect on the anticoagulant. A small diminution
in the anticoagulant effect was noticed in samples stored
at 4°C. for a few weeks. The anticoagulant maintained its
potency at room temperature for LB hours and after heating
at 56°C. for 30 minutes, but lost 27 per cent of its
potency after heating for 10 minutes at 72°C. At 80°C.
it was impossible to demonstrate the anticoagulant because
of denaturation of the whole plasma proteins,
3. Effect of organic solvents, ether and chloroform.
Plasma samples separately extracted in the cold with
2 volumes of either solvent for 30 minutes did not lose
their anticoagulant power.
L-. Effect of inorganic adsorbants.
Aluminium hydroxide and barium sulphate adsorbed plasmas
showed no loss of anticoagulant activity.
5. Plasma dialysis.
The patient's plasma was dialyzed against veronal buffer pH
7.5 at 4°C. for 24 hours during which time the buffer was
changed 5 times. The anticoagulant activity was minimally
96
affected.
6. Activity of plasma protein fractions.
The plasma proteins were precipitated by various concentrations
of ammonium sulphate. After dialysis of the fractions and
reconstitution to the original plasma volume with veronal
buffer the inhibitory activity of each fraction was assessed.
The anticoagulant was not limited to one fraction (Table XI).
7. Immune antibodies.
No immune antibodies could be detected in the patient's
plasma against a purified preparation of Antihaemophilic
Fraction, nor against normal or haemophilic plasmas by
Grabar Immunoelectrophoresis and Ouchterlony precipitin
tests.
Discussion
That the patient had classical haemophilia was proved by the
clinical and family history and by the low level of factor VIII in his
blood. The potent anticoagulant effect of his plasma against normal
plasma is demonstrated in Table X, an effect which was obvious even
where the patient's plasma was present in as low a concentration as
10 per cent.
The anticoagulant here was neither acting in the fourth stage of
clotting i.e. stage of fibrin 'dissolution', nor in the third stage (fibrin
formation). The fibrinogen content of the patient's plasma was normal.
No increase in spontaneous fibrinolytic activity was demonstrable. The
ultimate clot was normal in volume, tensile strength and retractability.
That there was no evidence of heparinoid activity was shown by the constantly
normal thrombin time both before and after addition of toluidine blue.
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The anticoagulant was not acting in the second stage of the
clotting mechanism (prothrombin activation stage) as was shown by a
normal one-stage Quick prothrombin time. Presumably also the
anticoagulant effect was not directed against the activity of the
intrinsic or extrinsic thromboplastins, factor 7, factor VII or factor X
(Stuart Prower factor).
That factor IX (Christmas factor), factor XI (PTA, Rosenthal factor)
and factor XII (Hageman factor) were not antagonized was shown by the
normality of the serum. The patient's platelets were present in normal
numbers and they behaved normally in the thromboplastin generation mixture.
The patient's factor VIII blood level was 18% and transfusion with Anti-
haemophilic Fraction raised the level by the anticipated amount to within
normal limits. This did not, however, rectify the clotting mechanism.
Incubation of normal plasma with the patient's plasma did not decrease
its factor VIII content. A normal clotting time obtained when the patient's
plasma was used as a fibrinogen substrate in the thromboplastin generation
test confirmed the lack of antagonism of the anticoagulant to the generated
plasma thromboplastin. The site of action of the anticoagulant could
therefore only have been in the interaction phase between the various
factors necessary for the plasma thromboplastin generation.
The anticoagulant was present in the patient's plasma but was absent
from his serum. It was heat stable, only minimally affected by
dialysis and not confined to any one salt precipitated plasma
protein fraction. It was not soluble in lipid solvents and not adsorbed
by inorganic protein adsorbents. It did not appear to be of the nature
of a gamma globulin immune antibody. The apparent antagonization of the
anticoagulant in the patient's plasma produced by alternatively freezing
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and thawing it and the similar effect of normal plasma so treated on the
patient's untreated plasma cannot be unequivocally explained; it might
be due to platelet contamination and destruction with release of thrombo¬
plastin as suggested by Sj^lin (1959).
Tocantins' antithromboplastin is claimed to be present in excessive
amounts in haemophilic blood. By definition it is an activity existing
probably in the form of a lipoprotein in the tissues, blood plasma and serum,
directed against the formation and action of thromboplastin. In order to
demonstrate it, special techniques have to be used or it is destroyed
(Tocantins, 1955). No special precautions were taken in our experiments
in that respect and yet the anticoagulant effect still remained. For these
various reasons, the anticoagulant met with in this case is considered to be
a substance different from the antithromboplastin described by Tocantins.
In some patients sensitization to the Rh - Hr system of blood factors
from previous transfusions can give rise to a circulating anticoagulant
(Stefanini and Dameshek, 1955). This was not the case in our patient, no
antibodies being detected over a wide range of temperature and the direct
Coombs' test being negative.
The so-called "Bridge Anticoagulant" (Nour-Eldin and Wilkinson, 1958)
has not to our knowledge been characterized. This phenomenon has now been
re-evaluated and endowed with a new conception (Serafini, 1959) in that
a plasma containing an incomplete thromboplastin such as haemophilic plasma
may cause a normal plasma to clot in a shorter time than plasma lacking the
same factor because in the former case thromboplastin formation can be
completed and further activated by the substrate plasma. Such a phenomenon
concerns not only the deficiency of antihaemophilic factor, but even that
of the other thromboplastin factors. Indeed it can be proved that, when
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thromboplastin is generated with a deficiency of platelet factor, it clots
platelet-rich plasma in a shorter time than platelet-poor plasma. This
point of view has been also supported by the research of Hougie (1959).
It is difficult to explain this patient's lifelong episodes of
haematuria on a haemophilic basis alone in that he had no other spontaneous
manifestations of the haemophilic state and only had two haemarthrotic
episodes both to trauma during his lifetime. His incapacity was indeed
only due to his episodes of haematuria and until the last illness these
responded to rest and a short period of transfusion.
Necropsy showed bilateral hydronephrosis and hydroureter of
moderate degree and it is hardly conceivable that this was a basic
cause of the haematuria. What part, however, it played in his final
illness we do not know. Reports on the association of renal lesions
with haemophilia are meagre, and the association of even weak circulating
anticoagulants with kidney disease accompanied by haemorrhagic tendency
seems to be rare (Willoughby and Crouch, 196l).
Summary
(1) A description is given of a circulating anticoagulant that
occurred in a patient with classical haemophilia. The anticoagulant
blocked the interaction of the thromboplastin generation components
but did not destroy factor VHI0
(2) A clinical study and a laboratory attempt at the characterization
of the anticoagulant is presented.
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I The Fibrinolytic System
A review of the literature is presented together with an
evaluation of the present methods for the measurement of its
parameters.
The methods adopted in the course of this study include (l)
the heated fibrin plate for the estimation of plasmin, (2) the
plasma euglobulin lysis time for the determination of the overall
"fibrinolytic activity" and/or the activator, (3) a caseinolytic
method for the measurement of plasminogen and (A) an assay of
antifibrinolysins.
(a) A study of the fibrinolytic system in some congenital and
hereditary haemorrhagic disorders was carried out in order to
evaluate the theory that, in vivo, the coagulation and the fibrinolytic
processes normally exist in a state of dynamic equilibrium. It
was thought that if this theory held true, then a change in one of the
components of the equilibrium state, (for example a delayed or dim¬
inished coagulation mechanism as in certain haemorrhagic disorders)
would lead to a balancing diminution in the other component and hence
to a decrease in fibrinolytic activity. It was found that the
fibrinolytic system was normal in these states and that its activation
during and following operative procedures,followed a normal sequence.
These findings may cast some doubt on the theory of physiological
dynamic haemostasis.
(b) The changes in the fibrinolytic system observed in eighteen
patients with cardiac disease undergoing open-heart surgery on cardio¬
pulmonary bypass with hypothermia were studied. This revealed that
excessive fibrinolysis is inevitable at some time during the procedure,
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but need not, however, cause any serious consequences as shown
in the patients studied. Plasminogen and fibrinogen diminution
was noted, while changes in the aatifibrinolysins were less clear.
II A Comparison of Haptoglobin Phenotypes in
Haemophilics and Normal Persons in Scotland
Haptoglobin phenotyping by starch-gel electrophoresis was
done in thirty-eight patients with haemophilia and other congenital
and hereditary haemorrhagic disorders, and in one hundred normal
individuals in Scotland. This study was undertaken in an
endeavour to find a genetic link for these conditions and as a
way of investigating the relation between blood groups and/or
haptoglobin types and disease states.
Haptoglobin type distribution in these conditions matched
that in the control series which, in its turn, was in accord with
that of neighbouring populations.
III Plasma Thromboplastin Generation
Blocking Anticoagulant in Haemophilia.
Glinico-Pathological Study of a Refractory Case
This investigation presented a clinical study, together with
an attempt at the characterization of and speculations on the
aetiology of an unusual form of circulating anticoagulant which
developed in a patient with classical haemophilia. The anticoagulant
in this case blocked the interaction leading to the generation of
plasma thromboplastin activity, but did not destroy factor VIII.
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